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A patent foramen ovale is a remnant of the foetal circulation that exists between the right atrium 
and the left atrium of the heart. It is estimated to be present in 1 in 4 adults in the general 
population. The presence of this residual hole can allow the passage of microemboli into the 
arterial system, which can then travel to the brain causing an ischemic stroke. A subtype of 
ischemic stroke is a cryptogenic stroke, which occurs when the initial cause of ischemia cannot 
be determined. The presence of a patent foramen ovale is more common in patients with 
cryptogenic stroke, suggesting a relationship. Currently, the most common method of detection 
for a patent foramen ovale is transthoracic echocardiography, which is often followed by 
transoesophageal echocardiography if the remnant is suspected and requires further 
investigation. An alternative method of diagnosis is transcranial Doppler, which has 
demonstrated diagnostic superiority in some studies. The use of all three imaging techniques 
are commonly utilized clinically, but the optimal method is still under debate.  
In this thesis, the two bedside techniques transthoracic echocardiography and transcranial 
Doppler were applied to a case series of three patients with suspected patent foramen ovale that 
were referred on to the cardiology unit after an ischemic stroke, or possible cryptogenic stroke. 
Additionally, a systematic review and meta-analysis was undertaken to assess the status of the 
two diagnostic techniques in literature.  
The case studies uncovered some significant pitfalls and advantages of both transthoracic 
echocardiography and transcranial Doppler, while still diagnosing all three case studies 
positively with a patent foramen ovale.  
The systematic review and meta-analysis found that the sensitivity of the two bedside 
techniques changed when the gold standard reference technique, transoesophageal 
echocardiography, was included. Prior to its inclusion, the two techniques had similar levels of 
sensitivity, but on inclusion, transcranial Doppler appeared to be the optimal technique for the 
ruling in of a patent foramen ovale, while transthoracic echocardiology appeared to be the 
optimal technique for the ruling out of a patent foramen ovale. 
Discrepancies between the detection techniques continue to emerge throughout literature, 
indicating the need for further investigation into the determination of the optimal technique, as 
well as methods that can be applied to optimize each technique. The treatment of a patent 
foramen ovale can be lifesaving, but an accurate initial diagnosis is needed to facilitate making 
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Chapter One: Introduction 
Stroke 
Stroke is one of the most devastating and debilitating neurological diseases that affects over 
9,000 New Zealanders every year.1 The most common form of stroke is an ischemic stroke, 
which is caused by the blockage or occlusion of a cerebral blood vessel by a microemboli and 
accounts for ~80% of all strokes.2 The less common form of stroke is a haemorrhagic stroke, 
which typically involves the rupturing of a cerebral blood vessel, and the consequential blood 
leakage into the brain, leading to swelling and cell death.3 A cryptogenic stroke (CS) is a stroke 
of unrecognised or unknown origin.4 Around 40% of ischemic strokes are classified as 
cryptogenic, where no root cause has been determined following check-ups and testing.5 A 
transient ischemic attack (TIA) is commonly referred to as a ‘mini-stroke’, due to its effects 
lasting for an acute period of time (<24 hrs), rather than permanently.6 A CS is known to be 
transitory or reversible, meaning it was initiated by a risk factor that can be reduced, avoided, 
or abolished to prevent the stroke from ever reoccurring.7 A patent foramen ovale (PFO) is a 
remnant of the foetal circulation that allows the passage of deoxygenated blood into the arterial 
system, and is therefore a potential mechanism for cryptogenic stroke. 
 
Risk Factors for Ischemic Stroke 
There are a variety of risk factors for ischemic stroke, but the largest risk factor is age, with the 
probability of stroke doubling every ten-years once an individual has reached 55-years of age.8 
Other clinical risk factors include, but are not limited to: health conditions such as diabetes, 
obesity, heart disease, and hypertension, as well as cigarette, alcohol, and recreational drug 
use.3 Lastly, the male sex is a risk factor for stroke, with the incidence of stroke being 1.5 times 
higher in males compared to females.6  
 
What is a Patent Foramen Ovale  
A PFO is a common remnant of the foetal circulation that exists between the right atrium (RA) 
and left atrium (LA).9 The failed fusion of the flap-like structure called the septum primum to 
the septum secundum leaves a tunnel between the two layers of the septum, clinically referred 
to as a PFO (Fig. 1).10 Depending on the anatomy and the difference in pressure between the 
RA and LA, the flap-like structure may allow various degrees of right-to-left shunt (RLS).10 A 
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RLS is characterised by the movement of venous blood into the arterial circulation.11 The 
diameter of a PFO can vary from 1 to 19mm, with the average diameter increasing with age.12 
Studies estimate that 1 in 4 adults in the general population have a PFO.13,14  Autopsy studies 
investigating the presence of a PFO demonstrate that the prevalence in the general population 
is close to 25%, but found that incidence decreased with age (34.3% in the first three decades 
of life, compared to 25.4% in the fourth through eight decades, and 20.2% during the ninth and 
tenth decade).15 The prevalence of PFO appears to increase in individuals with other conditions 
such as CS, sleep apnoea, decompression sickness, or migraine.16,17  
 
1. Anatomy of a PFO 
 
Figure 1:A schematic of the structure of a PFO. Abbreviations: PFO = patent foramen ovale, RA = right atrium, RV = right 
ventricle, LA = left atrium, LV = left ventricle. Image reprinted from ‘Patent foramen ovale: a new disease?, Drighil et al., 
Figure 1, Copyright (2007), with permission from Elsevier. Licence number: 4865060470694 
 
Ischemic Strokes and Patent Foramen Ovale 
A PFO provides a route for venous blood and therefore microemboli into the arterial system 
and has been linked to CS.18 It can also cause systemic embolism, which is when a microemboli 
gets trapped in the vascular supply of an organ, causing dysfunction.19 Under normal 
circumstances, the lungs would filter out any venous microemboli,17 but in the presence of PFO 
it is possible for microemboli to travel into the left heart, through the aorta and up to the brain.20 
When a microemboli passes from the venous to the arterial system, it is called a paradoxical 




ischemic stroke.19 The prevalence of a PFO in CS patients has been shown to range from 24% 
to 59%.22–25 Specifically, young patients (<55 years) who experience a CS have a higher 
prevalence of PFO (between 48-56%) compared to patients experiencing a stroke of recognised 
origin (4-20%).4,26,27 It has also been reported that medium to large PFOs (≥2 mm) are more 
common in patients presenting with CS (26% of total PFOs found were medium or large) 
compared with stroke of known origin (6% of total PFOs found were medium or large).28 Other 
mechanisms of PE such as the presence of a pulmonary arteriovenous fistula, atrial septal 
defect, or an atrial septal aneurysm can also cause a stroke.13 One particular study by Mas et 
al., investigated young CS patients (<55 years) and found that 36% had a PFO, 1.7% had an 
atrial septal aneurysm, and 8.5% had both a PFO and an atrial septal aneurysm.29 Paradoxical 
embolism as a result of CS tends to be more common in patients that have an absence of the 
traditional risk factors for ischemic stroke (older age, obesity, hypertension etc.).30 The Risk of 
Paradoxical Embolism (RoPE) score has been developed to help identify the likelihood of the 
CS being caused by a PFO.31   
 
The Risk of Paradoxical Embolism Score 
The RoPE score was developed in 2013 by Kent et al., and involves a 10-point system used to 
stratify patients with CS and predict the contribution of the PFO to the presenting condition 
(Table 1).31 It is used to ensure that the cause of CS is correctly attributed to a PFO, rather than 
the PFO being an ‘innocent bystander’ or incidental finding, which, given the prevalence of a 
PFO in the general population being up to 25%, may be likely.30 The RoPE score considers 
variables such as age, presence of a cortical infarct on imaging, and the absence of factors such 
as diabetes, hypertension, smoking, and prior ischemic event. It calculates a 10-point score that 
predicts likelihood of the PFO being causal to the CS, as well as the risk of recurrent stroke.31 
The validity of this score was explored by Prefasi et al., in 2016 who concluded that a RoPE 
score of 7 was the cut off for validity.32 They found that in a cohort of 58 CS patients, a RoPE 
score of 7 or under indicated a 0% chance of the CS being attributable to a PFO, compared to 








Table 1: RoPE score calculator 
Characteristic Points RoPE score 
No history of hypertension 1  
No history of diabetes 1  
No history of stroke or TIA 1  
Non-smoker 1  
Cortical infarct on imaging 1  
Age, years   
18-29 5  
30-39 4  
40-49 3  
50-59 2  
60-69 1  
≥70 0  
Total score (sum of individual points)   
Maximum score (a patient <30 years with no hypertension, no 
diabetes, no history of stroke or TIA, non-smoker, and cortical 
infarct) 
 10 
Minimum score (a patient ≥70 years with no hypertension, 
diabetes, prior stroke, current smoker, no cortical infarct) 
 0 
Legend 1: The characteristics used to calculate the RoPE score and the value assigned to each. Available online at 
https://www.mdcalc.com/risk-paradoxical-embolism-rope-score. Abbreviations: RoPE = Risk of Paradoxical Embolism, TIA 
= transient ischemic attack 
 
Migraine and Patent Foramen Ovale 
A migraine headache can be characterised by the reoccurring symptom of a headache, as well 
as nausea, vomiting and other neurological-type dysfunctions.10 The mechanism and 
pathophysiology behind migraine is yet to be fully understood,33 yet studies show that there is 
a relationship between migraine and PFO. Zito et al found that 57% of patients with migraine 
had a PFO,34 and West et al., found that 79% of patients with migraine and CS had a PFO.24 
Giardini et al., conducted a study investigating the effects of PFO closure on migraine with 
aura patients (recurring migraine paired with sensory disturbances) and found that after a 
follow-up within 2-years, migraine with aura was eliminated in 83% of the patients, and a 
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further 8% felt as though there was a reduction of symptoms.35 On the contrary, one recent 
study by Mattle et al., also investigated the closure of PFO in migraine with aura patients, and 
found the closure to have no effect on the patients reoccurring migraines.36 It is obvious that 
there is a relationship between migraine and PFO, but the mechanism to which still requires 
investigation.  
 
Other Shunts Similar to a Patent Foramen Ovale 
Congenital malformations such as an atrial septal defect, atrial septal aneurysm, or a pulmonary 
arteriovenous fistula can also facilitate a RLS. These defects can be intracardiac (atrial septal 
defect or atrial septal aneurysm) or intrapulmonary (pulmonary arteriovenous fistula), and 
despite clear anatomical differences often end up causing the same health conditions. An atrial 
septal defect is a congenital heart disease and is known to be present in up to 0.2% of children.37 
While an atrial septal defect and a PFO exist in the same anatomical area (the septum), an atrial 
septal defect is a fixed opening of the septum which allows the passage of blood from one atria 
to the other without the need of a pressure gradient like a PFO.38 An atrial septal aneurysm on 
the other hand, is more common than an atrial septal defect and is estimated to be present in 
around 1% of the population, but this proportion is increased when the patient presents with a 
condition such as a stroke or migraine.39 It can be characterised by the bulging of remnant 
septal tissue into both the left and right atria.40 The most common intrapulmonary shunt is a 
pulmonary arteriovenous fistula, which is a vessel malformation causing a connection between 
the pulmonary circulation and the systemic circulation, allowing deoxygenated blood to bypass 
the lungs.41 An autopsy study showed only 3 in 15,000 individuals had the malformation.42  
 
Optimisation of Diagnostic Tests 
Sensitivity and specificity are measurements commonly used to evaluate a clinical test. 
Sensitivity refers to the tests ability to correctly identify patients with the condition, while 
specificity refers to the tests ability to correctly identify patients without the condition.43 Both 
are measured as a percentage, and are usually measured using a gold standard reference test.43 
A gold standard test, also known as a reference test, is a test that is independent of the index 
tests that can indicate the true condition state of the patient.44 It is used to compare the 
diagnostic abilities of the index tests and to calculate sensitivity and specificity.44 Sometimes 
the reference test is unavailable or imperfect, so other mathematical modelling methods can be 
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used to estimate sensitivity and specificity, such as the maximum likelihood estimation and 
Bayesian inference.45 
 
Diagnosis of Patent Foramen Ovale 
There are three imaging methods that are clinically used to detect a RLS for the diagnosis of a 
PFO. Transthoracic echocardiography (TTE) directly images the heart and is most commonly 
used by cardiologists as the initial diagnostic test.9 Transcranial Doppler (TCD) is often used 
by neurologists, which instead of imaging the heart directly, measures the blood velocity 
profile in the cerebral arteries.46 Transoesophageal echocardiography (TOE) is the current 
clinical gold standard for diagnosis and is used after positive or suspected diagnosis of PFO 
from either TTE or TCD.47  
 
Valsalva Manoeuvre 
The Valsalva manoeuvre is a provocation that is commonly used concurrently with the three 
diagnostic imaging methodologies for PFO diagnosis. It can improve RLS visualisation and 
thus PFO diagnosis by up to 28%.48 The Valsalva manoeuvre involves four phases; (1) the 
patient forcefully expires against a closed glottis which briefly increases the intrathoracic 
pressure, initially reducing venous return; (2-early) while the patient is still forcefully expiring 
venous return continues to decrease and as a result stroke volume drops resulting in a decrease 
in blood pressure; (2-late) the activation of the baroreflex increases the heart rate and 
subsequent blood pressure; (3-release) the patient releases abdominal pressure and blood flow 
returns to the heart, resulting in a decrease in intrathoracic pressure and the normalization of 
blood flow; (4) blood pressure overshoots as the heart refills.49 The change in intrathoracic 
pressure during the Valsalva manoeuvre produces a positive right-to-left pressure gradient 
between the RA and the LA that would prompt a RLS if a PFO were present.50 A well 
performed and well timed Valsalva manoeuvre is crucial for PFO detection as it prompts the 
contrast to move from the RA into the LA where it can then be imaged, either directly by TTE, 
or indirectly in the middle cerebral artery (MCA) by TCD.51 If the Valsalva manoeuvre is 
performed at the wrong moment, the patient may miss the window when the LA is opacified, 
which may result in a RLS without contrast that could lead to a false negative result. There are 
several different procedures for the provocation of the Valsalva manoeuvre. Some clinicians 
use a taught Valsalva manoeuvre (where the patient bears down against a closed glottis or 
thumb in mouth);48 some use a calibrated device (such as a sphygmomanometer);52 some use 
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a coughing technique;53 and some use abdominal compression paired with a Valsalva 
manoeuvre.54 However, the choice and use of each method does not appear to be standardised.52 
Using a calibrated device can mimic a Valsalva manoeuvre by helping the patient maintain a 
constant intrathoracic pressure by blowing into a tube attached to a sphygmomanometer.52,55 
However, it is hard to know whether the pressure maintained on the sphygmomanometer is 
from the closure of the palate or the elevated intrathoracic pressure, although changes in heart 
rate and blood pressure can give indication to a genuine change in intrathoracic pressure.56 
Some clinicians apply abdominal compression during the Valsalva manoeuvre which further 
increases intrathoracic pressure, in turn decreasing venous return and left atrial pressure, 
enhancing the right-to-left pressure gradient that is needed to provoke a RLS.51 This method is 
particularly useful for patients unable to perform an adequate Valsalva manoeuvre due to health 
conditions such as obesity, or if they were undergoing a TOE that required partial sedation.54 
Abdominal compression can improve the accuracy of TOE,54 and can improve the sensitivity 
of TTE from 85% to 99% compared to a normal Valsalva manouevre.51 
 
Saline Injection 
Agitated saline is an inexpensive and effective contrast agent that is injected into the venous 
circulation during TTE, TCD and TOE for PFO diagnosis. The contrast is composed of 
microbubbles and is highly reflective of ultrasound compared to blood (which does not reflect 
ultrasound). The movement of blood that includes contrast can then be directly visualised using 
TTE, TOE or TCD.57 A PFO is believed to be present if the contrast is seen in the LA, left 
ventricle (LV) or MCA. This is because the PFO provides a route for the contrast to cross the 
interatrial septum into the arterial system. If no PFO was present, the microbubbles would be 
filtered out by the lungs and no contrast would be visualised in the systemic circulation. The 
contrast’s efficacy is improved when a small amount of blood (1 ml) is mixed into the 
saline.58,59 The sensitivity of TTE and TCD is also improved by giving repeated saline 
injections.60,61 The injection site has traditionally been via the brachial vein in the arm,62 but 
higher sensitivity for PFO detection using TCD has been demonstrated when the agitated saline 
is injected via the femoral vein (50%) compared to the brachial vein (18%).63 This is believed 
to be related to the direction of the inflow of the venous blood into the RA. Venous blood from 
the upper limb enters the RA via the superior vena cava, and directly traverses the tricuspid 
valve. Whereas femoral venous blood enters into the RA via the inferior vena cava and is 
directed towards the atrial septum. Blood from inferior vena cava is therefore more likely to 
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pass through the PFO if present.63–65 The Eustachian valve, is another remnant of the foetal 
circulation located at the entrance of the inferior vena cava into the RA.17 During foetal 
circulation it directs blood flow towards the foramen ovale, but if present in an adult would 
help to keep the foramen ovale patent.17 The presence of this valve impairs the inflow of saline 
from the superior vena cava if injected by the arm. However, if saline is injected via the femoral 
vein, the contrast comes into the RA through the inferior vena cava and is directed right at the 
septum.66 This has been shown to increase the reliability of detection.66 Since TCD, TTE and 
TOE are all relatively similar in the way they detect a RLS (i.e. they require the agitated saline 
to pass through the PFO), it is likely that a change in injection site would also increase 
sensitivity of these methods, which has been demonstrated in studies by Hamann and Gin.62,63 
However, given the additional complexity and potential risk associated with femoral venous 
cannulation, this technique is likely to remain restricted to patients with a high suspicion of 
PFO but negative initial imaging studies. 
 
Transthoracic Echocardiography 
Transthoracic echocardiography (TTE) uses an ultrasound probe applied to the chest wall that 
uses high frequency sound waves to take still or moving images of the heart and its internal 
features. It can be used to assess and measure a variety of suspected problems, such as valve 
dysfunction, heart muscle contraction, and abnormal heart size and rhythm.67 It is commonly 
used for the diagnosis of PFO by either imaging the interatrial septum directly, or paired with 
agitated saline contrast which can image the highly reflective microbubbles travelling between 
atria.68 The TTE with agitated saline injection is typically the first diagnostic test implemented 
due to its ease of use, relatively low cost, and proven diagnostic ability. In some cases, 
microbubbles do traverse from the RA to LA at rest, confirming the presence of a PFO. This 
would usually occur within the first three cardiac cycles after opacification of the RA.69 
However, if this does not occur, the patient is then asked to perform the Valsalva manoeuvre 
(Fig. 2). The shunt is assessed during the first three to four heart beats following the release 
phase of the Valsalva manoeuvre.48 The timing is important, since the presence of an 
intrapulmonary shunt will also allow microbubbles to pass into the arterial circulation, but with 
a time delay.70 In the absence of a PFO, no opacification of the LA is observed, but if a PFO is 
present, the severity of the shunt can be graded based on the number of microbubbles observed 
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traversing the foramen ovale as mild (<10 microbubbles), moderate (10-20 microbubbles), or 




Figure 2: (A) Transthoracic echocardiogram four chamber view of the heart at rest prior to the agitated saline injection. 
(B) Opacified right heart during the agitated saline injection. (C) Multiple microbubbles indicated by the arrow can be 
seen in the left atrium and some have moved into the left ventricle following the release phase of the Valsalva 
manoeuvre. Abbreviations: TTE = transthoracic echocardiography, RV = right ventricle, LV = left ventricle, RA = 
right atrium, LA = left atrium. Image obtained with permission from the Southern District Health Board. 




Transcranial Doppler (TCD) is an ultrasound technique that images a chosen cerebral blood 
vessel using an ultrasound probe applied to the temporal bone window of the head. It is 
becoming increasingly popular for the assessment of cerebral blood flow change, vascular 
stenosis, or to detect embolic signals within the arteries.71 TCD can also be used to clinically 
diagnose several cerebrovascular disorders, such as vasospasm, sickle cell disease, or brain 
death.71 The TCD imaging method for the non-invasive detection of PFO involves insonation 
of the major cerebral arteries, typically the MCA, with a standalone Doppler transducer to 
assess blood velocity profile. The Doppler system can be used for unilateral and/or bilateral 
imaging. The portable 2 MHz pulsed wave Doppler transducers are held securely in place with 
a specialised headband over the temporal bone window and are manipulated to optimise the 
blood velocity signal of the cerebral vessel of interest. This is visualised as a red band of blood 
flow signal if the blood is flowing towards the transducer, and a blue band if the blood is 
flowing away from the transducer72 (Fig. 3). Modern TCD systems can display multiple vessels 
at once at different depths. The top screen displays the power M-Mode™ TCD (PMD-TCD; 
33 sample gates) of all the vessels within the sampling depth range field. The yellow reference 
line on the top portion of the screen is the depth (in mm on the y-axis) at which the spectrogram 
(single-gate) velocity waveform on the bottom of the screen is derived, insonating the artery of 
interest (Fig. 3). The combination of PMD-TCD and the spectrogram increases the sensitivity 
of TCD for diagnosing a PFO.73 If a RLS is present at rest or during the Valsalva manoeuvre, 
the clinician will visualise the microbubble contrast and hear audible blips. A RLS of any type 
is considered present if at least one microbubble is recorded with TCD within 25 seconds of 
injection of the agitated saline.74 The ‘rule of nine’ was developed in 2010 by Lange et al., 
which helps the clinician differentiate between intracardiac and intrapulmonary shunts by 
considering three markers in the case of a positive test such as number of microbubbles, as well 
as the latency time and duration time of the microbubbles.75 The RLS and size of the potential 
PFO is graded based on the number of microbubbles: grade 1 (1 – 10 microbubbles), 2 (11 – 
30 microbubbles),  3 (31 – 100 microbubbles), 4 (101 – 300 microbubbles), and grade 5 (>300 







3. TCD with and without Microbubbles 
 
Figure 3: The arrow indicates the vessel of interest which is being insonated by the probe at the depth of the yellow reference 
line. (A) shows the vessel with no microbubbles present, and (B) with microbubbles (visualised as white disruption through 
the vessel of interest). Image obtained with permission from the Southern District Health Board. 
4. The Five grades of PFO severity using TCD 
 
Figure 4: TCD screen shots of the 5 different grades. The presence of contrast passing through a vessel is obvious both visually 
(as a white mark running through the signal) and audibly. Abbreviations: TCD = transcranial Doppler. Image reprinted from 
‘Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent Foramen 




Transoesophageal echocardiography (TOE) is commonly used for assessment of heart size, 
valve function, vegetation, as well as valvular regurgitation or stenosis.76 It is considered the 
gold standard method of PFO diagnosis.50 It provides high resolution imaging of the atria and 
interatrial septum, as the transducer (3-8 MHz) is placed in the oesophagus within close 
proximity to the heart.69,77 TOE is often used following a positive or probable TTE or TCD to 
confirm the presence of a PFO, and to exclude the presence of additional defects, especially 
atrial septal defects.77 During a TOE, patients must swallow the ultrasound probe, and sedation 
if often needed to minimise discomfort. Once the transducer is in position, the septum can be 
viewed from multiple angles allowing the best possible view for the presence or absence of a 
PFO (Fig. 5A). If discovered, the PFO and the associated anatomy can be assessed for 
suitability for transcatheter closure.70 As in a TTE and TCD, agitated saline may be injected 
(Fig. 5B) and the patient may be asked to perform the Valsalva manoeuvre if no bubbles 
traverse at rest. Anaesthetic or sedation is normally required for a TOE and this can limit the 
patient’s ability to perform a Valsalva manoeuvre, potentially impacting the sensitivity of this 
method.73 The same shunt grade as TTE is used to assess the RLS during the TOE. 
 
5. TOE of the heart during a Bubble Study 
 
Figure 5: The heart visualised using TOE before (A), and after (B) the injection of agitated saline. Abbreviations: TOE = 
transoesophageal echocardiography, IAS = interatrial septum, RA = right atrium, LA = left atrium. Image obtained with 
permission from the Southern District Health Board. 
 
Status of the Detection Techniques in Current Literature 
There is debate around which method of detection is most sensitive and most specific for PFO 
detection, and studies show a significant amount of variation. Separate meta-analyses 
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investigating the sensitivity and specificity of each individual technique found TCD to be the 
most sensitive (97% for TCD, versus 88% for TTE and 89% for TOE). Contrastingly, the same 
studies found TTE to be the most specific (97% for TTE, versus 93% for TCD and 91% for 
TOE).16,78,79 The implications of these variations can result in the false positive or false 
negative diagnoses of PFO. The clinical implications of a false negative diagnosis can result in 
the recurrence of a cerebral event due to the PFO not being identified, and therefore the correct 
method of treatment (if necessary) may not be made. A false positive diagnosis may result in 
the patient undergoing a TOE for further assessment, which comes with risk (such as damage 
to the throat or oesophagus).70 
 
Head-to-Head comparison of TTE and TCD 
Despite advocacy and professional preference for one technique over the other, few studies 
have conducted head-to-head comparison of these techniques. The diagnostic capabilities of 
TTE and TCD seem to be reasonably even, but there are methodological differences. While 
TTE images the heart and therefore the contrast directly, TCD images the MCA. TTE is reliant 
on the visualisation of microbubbles, whereas TCD can not only visualise a microbubble 
travelling through the MCA, but audible blips can also be heard.80 TOE is often used as a gold 
standard reference technique against TTE or TCD, but very few studies have compared all 
three imaging techniques (TTE, TCD, TOE) for PFO detection in the same cohort (Table 
2).48,69,81,82 Of those that have, Gonzalez-Alujas et al., used the presence of a PFO in two of the 
three techniques as the gold standard.48 They found that the sensitivity and specificity of TTE 
(100% and 100%, respectively) was superior to TCD (97% and 98%, respectively).48 It is worth 
noting that the sensitivity of TOE was significantly lower (86%) than what might be anticipated 
compared to the other techniques.48 In some cases, TOE did not detect a PFO when both TTE 
and TCD did resulting in a false negative diagnosis in more than 10% of the cohort.48 In 
contrast, Maffe et al., reported that TOE was the optimal test. TOE detected the highest 
prevalence of PFO compared to TTE and TCD (PFO detected; N=62/75 vs N=55/75 and 
N=53/75).69 The sensitivity of TTE and TCD was 89% and 85%, and specificity 100% and 
95%, compared to TOE as the gold standard (100% and 100%).69 The lower specificity for 
TCD may be due to the method detecting other malformations such as a pulmonary 
arteriovenous fistula,83 or venous air embolism,84 which would lead to a false positive diagnosis 
of a PFO.82 Tullio et al., found that TCD was more sensitive than TTE. This was then attributed 
to suboptimal TTE image quality, led to false negative results.81 This study was conducted in 
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the early 1990s and since then we have seen significant advancements in ultrasound 
technology, which may lessen the occurrence of false negatives using either technique.81 
 
Table 2: Sensitivity and Specificity of TTE and TCD when compared to TOE 















Sensitivity 89% 100% 67% 54% 
Specificity 100% 100% 100% 94% 
PPV 100% 100% 100% 88% 





Sensitivity 85% 97% 78% 100% 
Specificity 90% 98% 100% 100% 
PPV 98% 99% 100% 100% 
NPV 53% 93% 100% 100% 
Legend 2: TTE = transthoracic echocardiography, TCD = transcranial Doppler, TOE = transoesophageal echocardiography, 
PPV = positive predictive value, NPV = negative predictive value 
 
Advantages and Pitfalls of Transthoracic Echocardiography 
Transthoracic echocardiography can be used by the bedside, is relatively inexpensive, non-
invasive, easy to use, and is a safe method of detection.85 However, it still comes with pitfalls 
(Table 3). A meta-analysis investigating the diagnostic ability of TTE found that it had a pooled 
sensitivity of 88%, and pooled specificity of 97%.78 To compromise on the lower level of 
sensitivity some studies claim that TTE is more sensitive when a cut off of <5 microbubbles is 
used.51 While this technique retains a high level of sensitivity and specificity in general, it may 
not be suitable for the assessment of smaller shunts.78 Image quality tends to be good in patients 
that are not overweight, but can be impaired when excess tissue lies between the heart and the 
probe.78 Image quality can also be affected by inflated lungs caused by exaggerated inspiration 
prior to the Valsalva manoeuvre.86 Suboptimal image quality can also make it difficult for the 
clinician to differentiate between an atrial septal aneurysm, atrial septal defect, or PFO.13 
However, the use of second-harmonic imaging has shown great improvements in the 
identification of smaller shunts and microbubbles.77 An additional advantage of TTE is the 
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ability to differentiate between intrapulmonary shunts and intracardiac shunts. When using 
TTE the contrast travelling through the PFO will appear within the first three cardiac cycles,69 
whereas if the shunt is due to a intrapulmonary shunt, bubbles are likely to appear after four or 
more cycles.87 
 
Advantages and Pitfalls of Transcranial Doppler 
Like TTE, TCD comes with significant advantages and pitfalls (Table 3). The average 
sensitivity of TCD tends be between 93% and 100%,68 however it tends to be less specific 
(78% - 100%).53,88 While TCDs primary pitfall is the inability to differentiate between 
intracardiac and intrapulmonary shunts, this can be negated by considering the timing of 
microbubble appearance. The ‘rule of 9’ is used to help with specificity, as it allows the 
clinician to identify the presence of a PFO if at least nine microbubbles pass through the MCA 
and appear within 9 seconds of injection.75,89 By evaluating the number of microbubbles 
travelling through the MCA, TCD is also able to assess the potential harm of the shunt. The 
‘curtain effect’ (characterised by so many microbubbles passing through the vessel of interest 
that no single microbubble can be distinguished) usually presents in patients that have had a 
CS.89 This can help clinicians distinguish between a ‘harmful’ RLS that can be caused by a 
mechanism such as a PFO which may cause further cerebrovascular events (such as a stroke), 
rather than a more ‘innocent’ shunt which may be an incidental finding, or is unlikely to cause 
recurrence due to an absence of presenting risk factors.89 Some advantages of TCD include the 
combination of visual and audible cues to detect microbubbles, it being cost effective, safe and 
easy to perform, and unlike TTE and TOE, inflated lungs does not affect image quality.85 
Another prominent disadvantage of TCD is the reliance of a temporal bone window. Studies 
show that the window is missing in 10-20% of the population, and that the absence appears to 
be even more common in females, the elderly community, and Black and Asian populations.71 
Alternatives to the temporal window have been proposed such as the orbital window,90 
vertebral artery,91 and vertebrobasilar circulation monitoring,80 all which all have competitive 
sensitivities and specificities for PFO detection compared to the temporal window. Another 
pitfall of TCD is its inability to visualise the efficiency of the Valsalva manoeuvre. Unlike 
TTE, TCD images the MCA, and therefore the user is unable to directly assess the interatrial 
septum to observe if the Valsalva manoeuvre prompted a shunt, and more importantly, a shunt 
that included blood with contrast.85 
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Advantages and Pitfalls of Transoesophageal Echocardiography 
TOE is generally considered to be the gold standard technique for PFO detection. However, 
Stafford et al., cumulated studies that were in agreement with the combination of TOE and 
TCD as a gold standard reference technique for PFO detection.68 They found that the highest 
accuracy for PFO diagnosis was observed when the two techniques were combined.68 Due to 
the close proximity to the heart, TOE has excellent image quality and therefore holds a 
significant advantage in the assessment of the septum for a specific diagnosis (i.e. PFO, atrial 
septal defect, atrial septal aneurysm, or intrapulmonary shunt) (Table 3). It is also able to assess 
the area for suitability for repair as it can grade the size and severity of the PFO clearly.85 
However, TOE tends to have a wider range of sensitivity (48 – 100%) and specificity (83 – 
100%) than other techniques, and has a higher rate of false negatives.68,92,93 Due to the semi-
invasive nature of the technique it can cause injuries to the throat, oesophagus, and stomach.86 
This means the patient is often at least partially sedated, which can prevent the patient from 
performing an adequate Valsalva manoeuvre.85 This makes TOE more susceptible to the false 
negative results and is its primary pitfall.34,48,68,85  
Table 3: Advantages and disadvantages of TTE, TCD, and TOE for PFO diagnosis 
 ADVANTAGES DISADVANTAGES 
TTE • Easy to use 
• Low cost 
• Non-invasive 
• Safe 
• Differentiate between intracardiac and 
intrapulmonary shunt 
• Suboptimal image quality 
• Lower sensitivity than TCD 
• Imaging window may effect image 
quality 
• Can be affected by obesity or inflated 
lungs 
TCD • Easy to use 
• Low cost 
• Non-invasive 
• Safe 
• More sensitive 
• Visual and audible cues 
• Not affected by suboptimal image 
quality 
• Cannot differentiate between 
intracardiac shunt types 
• If timing is not regulated cannot 
differentiate between intracardiac and 
intrapulmonary shunts 
• Less specific 
• Patient may have the absence of a 
temporal window 
• Cannot assess the septum directly 
TOE • Superior image quality 
• Able to assess the septum directly for 
shunt size, severity and suitability for 
repair 
• Can differentiate between intracardiac 
shunts 
• Invasive procedure 
• Sedation is often needed 
• Impairs the ability to perform an 
adequate Valsalva manoeuvre 
• Is known to diagnose false-negatives.   





If left untreated, a PFO can cause recurring issues, such as CS or systemic embolism.94 The 
rate of recurrent CS with no form of treatment is approximately 6% to 8% annually (with or 
without a PFO).12 When the PFO is treated, whether that be medically or using a closure device, 
the rates of recurrence have been shown to decrease to 2% to 4% annually.12 The RoPE score 
is a measure that helps determine the causal effect of the PFO to CS, and the risk of recurrence. 
A high RoPE score is indicative of the CS being attributable to the PFO due to the absence of 
traditional risk factors for ischemic stroke. However, a high RoPE score also indicates a rate 
of recurrence similar to that of a treated PFO (e.g. RoPE score of 10 suggests a 2% rate of 
TIA/stroke recurrence in the next 2 years).13,94 This is thought to be due to the traditional risk 
factors of ischemia (i.e. hypertension and smoking) being a more common, and therefore more 
likely mechanism of recurrence than paradoxical embolism through a PFO.94 It has also been 
shown that larger PFOs may indicate a lower risk of recurrent CS compared to smaller PFOs. 
This is thought to be due to larger shunts being the obvious cause of CS, with smaller shunts 
(otherwise known as ‘innocent shunts’) indicating the likelihood of a different, unknown 
mechanism causing the initial stroke, which could go on to cause a recurrent event.95 Because 
the mechanism behind recurrent CS after positive PFO diagnosis is still being discussed, some 
patients are treated for PFO while others are not.   
 
A PFO can be treated in several ways. The first involves PFO closure during open-heart 
surgery, which is extremely invasive and typically only takes place if the patient was 
undergoing open heart surgery for another reason. A much less invasive option is transcatheter 
closure of PFO (Fig. 6). In general, a catheter closure device accesses the RA via the femoral 
vein or the right internal jugular vein.96,97 The transeptal sheath travels through the PFO, and 
the distal arm of the PFO closure device is deployed into the LA, preventing it from retracting 
back through the PFO. The proximal arm of the closure device, still located in the RA, is then 
deployed. This creates a clamp-like structure over the PFO, bringing the two layers of the 
septum together and essentially closing the PFO. Alongside closure techniques, medical 
therapy is also seen as a traditional, long-term preventative option.18 Anticoagulants and 
antiplatelet agents such as warfarin or aspirin are commonly administrated to patients who are 
deemed to have a low-risk of a recurrent event.5 Several studies have investigated the different 
methods of PFO treatment, and found that PFO closure has the best result in terms of decreased 
recurrence.10,98 Khairy et al., found that over a 1-year follow up, the recurrence of medically 
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treated PFO patients ranged from 3.8-12%, while patients that had transcatheter closure had a 
recurrence range of 0-4.9%.99 Long term studies also demonstrate the superiority of closure 
over medical treatment. Saver et al., found that the prevalence of recurrent CS after 6-years 
follow up was 2% in the PFO closure group, and 4.8% in the medically treated group.100 Large 
scale studies my Mas et al., and Søndergaard et al., also suggest that PFO closure is superior 
to medical therapy.101,102 
6. PFO Closure using Amplatzer device 
 
Figure 6: A-D The process of the Amplatzer device being put into place: A, the sheath is in place across the interatrial septum, 
with the dot indicating the distal end of the device just outside the sheath; B, the left atrial side of the device is deployed; C, 
the right atrial side of the device is deployed; D, the sheath is removed and the device is locked in place. Abbreviations: PFO 





The presence of a PFO is high in the general population, and higher in patients who present 
with CS and migraine. In young people with cryptogenic stroke, the diagnosis of a PFO 
indicates if and what treatment is appropriate. While there are several techniques to image this 
residual defect, more clarity is needed to establish the optimal diagnostic approach due to 
contrasting levels of sensitivity and specificity between the different methods. In this thesis I 
aim to compare the two bedside techniques TTE and TCD, through direct evaluation and a 
systematic review of the current literature for PFO diagnosis using these imaging tools.  
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Chapter Two: Clinical Study – Patent 
Foramen Ovale Detection Methods 
Introduction 
Patent foramen ovale (PFO) is estimated to be present in around 25% of the general 
population,103 and 56% of patients with cryptogenic stroke (CS).12 Different methods are used 
clinically to detect the presence of a PFO, such as transthoracic echocardiography (TTE), 
transcranial Doppler (TCD), and transoesophageal echocardiography (TOE). Studies have 
shown that all three methods are reliable for the detection of PFO, however, there are 
discrepancies between which method is most sensitive and most specific. While TOE is widely 
regarded as the gold standard with a recent meta-analysis demonstrating a sensitivity of 89%, 
and specificity of 91%,16 both TTE and TCD challenge those statistics. In a meta-analysis by 
Ren et al., TTE was shown to have a weighted sensitivity of 88%, and weighted specificity of 
97% when 16 eligible studies using TTE for the diagnosis of PFO were compared.78 Mojadidi 
et al., did the same with TCD and found that it had a weighted sensitivity of 97% and a weighted 
specificity of 93% when 27 studies were compared.79  
 
While there is debate within the literature as to which standard is considered the best, there are 
few head-to-head studies comparing each technique in the same patients. Maffè et al.,69 
González et al.,48 and Zito et al.,34 all compared the three techniques in their corresponding 
cohorts. The sensitivity and specificity of TTE were superior to TCD in the both studies by 
Maffè and González,48,69 but the sensitivity of TTE was significantly lower than TCD in the 
study by Zito (94% vs. 55%).34 Katsanos et al., conducted a meta-analysis comparing studies 
that used either technique against TOE to determine what may be the optimal technique and 
found similar results to Zito in terms of the sensitivity of TTE (pooled sensitivity of TTE 45% 
versus 96% for TCD).93 While Katsanos et al., did not compare the two techniques in the same 
cohort, they analysed 35 studies, giving a very broad representation.93  
 
Each technique has pitfalls and advantages which contribute to the discrepancies between their 
sensitivities and specificities. For example, TCD struggles to insonate the middle cerebral 
artery (MCA) when a patient has an insufficient temporal bone window, and TTE struggles to 
image the heart when the patient has an insufficient acoustic window due to a condition such 
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as obesity.50,68 The use of the Valsalva manoeuvre is a common prompt that has shown to 
increase the sensitivity of all imaging modalities for PFO detection.52 However, the application 
of the Valsalva manoeuvre is not consistent throughout literature, as there are multiple ways 
that it can be prompted. While some clinicians use a trained or untrained Valsalva 
manoeuvre,104 others may use a coughing technique,52 calibrated device,73 or abdominal 
compression paired with the Valsalva manoeuvre to prompt a shunt.54 Because the use of the 
Valsalva manoeuvre improves the sensitivity of each diagnostic test, the different levels of its 
application are likely to affect the sensitivity of PFO diagnosis between studies. The present 
clinical study will compare TTE to TCD in three case studies where patients have either had a 
stroke, or stroke like neurological symptoms. The null hypothesis of the present study is that 
there will be no difference between TTE and TCD as a bedside techniques for PFO detection, 




Prior to the commencement of this project an intricate protocol was established in order to 
outline the direction and rationale of this project, as well as describe the methods used. This 
protocol was used to obtain locality, Human Disability Ethics Committee (HDEC) ethical 
approval and Māori consultation. The full protocol can be found in the appendix.  
 
Objectives 
This project aimed to investigate the optimal process of PFO identification in patients being 
investigated for possible cryptogenic stroke. Specifically, the clinical sensitivity and specificity 
of TTE and TCD will be compared. If the patient is referred on both methods will be compared 
to the gold standard TOE. It also aimed to evaluate different areas where agitated saline can be 
imaged (interatrial septum, aortic arch, and MCA). This project aimed to provide important 
information about the optimal approach to PFO detection and assessment of future embolic 
risk by adding to the current evidence regarding PFO diagnosis.  
 
Study Design 
Eligible patients were either consented in the ward or were called prior to the appointment for 
a postal or email address so the patient information sheet and consent form could be sent to 
them. If the patient consented to this research study, the patient also had their MCA circulation 
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assessed with TCD during the bubble study for PFO screening in addition to the normal 
echocardiographic assessment (TTE, and TOE if referred on). The registered sonographer also 
took images of the aortic arch following a successful Valsalva manoeuvre using TTE alongside 
the routine imaging. The ethical application allowed for the recruitment of 40-60 patients, but 
due to COVID-19, and the resulting restriction of hospital access to clinical patients, a cohort 
of that size was not viable. 
 
Recruitment 
Patients were approached for recruitment into this study when they were initially referred to 
the echocardiology team for a TTE following a suspected CS or systemic embolism. This 
included outpatients, and inpatients in the wards. Usual clinical practice for young patients is 
to undertake a bubble study during the same inpatient appointment as the structural TTE. 
During recruitment, it was made clear to the patients that the additional TCD test was to be 
conducted on the same day as the TTE, to avoid a return visit to the hospital. Only patients that 
fit into the following criteria were approached for this study. 
Inclusion 
- Patients that have been referred to the echocardiography service for a routine TTE after 
a CS or systemic embolus. 
- Over the age of 18. 
- Willing and able to provide informed consent. 
- Willing and able to comply with the study procedures. 
Exclusion 
- Have another identified potential cause of cardiac emboli other than PFO in their 
routine TTE (e.g. left ventricular thrombus, myxoma, vegetation on valve). 




Written informed consent was obtained prior to any data being collected. All participants were 
provided with a HDEC-approved participant information sheet and consent form that outlined 
the study rationale and expectations of them as participants. Additionally, as the head is 
regarded as Tapu (i.e. sacred) and cannot be touched in certain cultures, consent was granted 
by the participant following the complete understanding and agreement of the procedure that 
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would take place. They were then given the opportunity to ask questions, and if they chose to 
participate they signed the consent form. The consent process was documented, and the original 
consent form was filed in the research record. Participants were able to withdraw consent at 
any time and they were informed that the quality of their clinical care would not be adversely 
affected if they did not want to participate in this study.  
 
Confidentiality 
All study records and data collected during and after the study were stored in a secure area at 
the study institution. Each participant was given a unique study identifier that all the data was 
linked to. Data was held in a single central database. This database may be used for 
international comparisons in the future. If this were to be the case all analyses would be 
undertaken using the unique participant identifier and no information about participants would 
be released without their express permission. The only reason for doing so would be at the 
participant’s request or as a requirement for clinical follow-up. The latter would only occur if 
the participant granted permission. When data is released (for example in publications) all 
patient identifiers will be omitted.  
 
Risks and Benefits 
A minor potential risk was discomfort from the pressure of the ultrasound transducer and so 
measures were taken at all times to ensure the patient felt comfortable. There is typically a 
small amount of transient pain associated with the intravenous cannula used with the agitated 
saline injection, however this is part of the patients routine TTE. Every effort was made to 
minimize any discomfort the patient felt. 
The primary benefit produced of this study was adding to the literature regarding the 
management and assessment of CS patients, as well as the optimization of PFO detection 
methods. Patients that participated in this study also benefited from the additional assessment 
using TCD may have provided the clinician with more clarity for the diagnosis. This may have 
provided additional direction as to whether or not a TOE was to be conducted for further 
assessment regarding PFO closure.  
 
Ethics 
Ethics was sought via the HDEC expedited review pathway. Originally it was believed that 
Otago University Human Ethics Committee (OUHEC) (health) was needed, which is the 
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official Otago University ethics committee. This was declined after consideration and the 
application was escalated to HDEC. The final approval reference code is 19/CEN/201. Locality 
was also sought after and approved following HDEC ethical approval. This was approved 
under the project ID: 01590. Māori Consultation was sought, and support was given following 
the review of the research project.  
 
Amendments 
Once ethical approval was obtained, the time remaining for patient screening in this study was 
limited, and the number of in-patients that were eligible for the study were scarce. The decision 
was made to apply for an ethics amendment via HDEC to allow us to recruit out-patients that 
had already had their TTE completed, to invite them to attend for the TCD testing only. This 
amendment was provisionally approved, but by that time was no longer viable due restricted 
access to clinical patients for research personal as a result of COVID-19. 
 
Personnel 
Registered cardiac sonographers performed the TTE and I performed the TCD. As the testing 
was undertaken at the same time, blinding was not possible. However, when the testing was 
taking place I was focused on the TCD and ensuring the signal was strong throughout the 
Manoeuvre so I did not know the results of the TTE until they were given to me at a later date. 
The sonographer gave me the results of the TTE without knowledge of the TCD results. The 
sonographer was experienced and registered so the ability to conduct an adequate test for PFO 
presence was assumed. A reliability study in healthy volunteers was undertaken before testing 
the patients to establish technique proficiency, which is described prior to the procedures for 
the clinical patients. This involved 12 trial runs with participants, however, prior to this I had 
practised the technique thoroughly on volunteers and they were confident in my proficiency to 
perform the test.  
 
Reliability Testing of Transcranial Doppler 
Reliability testing was conducted on five healthy volunteers. Originally, participants were 
asked to come in three times over a period of months, however, due to COVID-19, only 2/5 
participants were able to complete all three trials, while the other 3/5 completed two trials. 
Trials were conducted at the same time on separate days. Participants were asked to keep 
factors that may influence their blood pressure or heartbeat consistent over the three trials, such 
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as coffee ingested, or method of commute into work. For the setup of the TCD, around 20ml 
of gel was placed on the participant’s temple just anterior to their ear. This was smoothed out 
to remove air bubbles within the gel that would disturb the signal. The headpiece was then 
placed over the participant’s head, with the backstrap sitting low and near the external occipital 
protuberance. The headpiece was then tightened slightly, but not completely. 50ml of gel was 
put on top of the probe, which was then put into place on the headpiece. The headpiece was 
then tightened so it was secure, but not tight enough to cause the participant discomfort. Once 
the probe was pressed onto the participant’s temporal bone window, it was turned on. The 
power of the ultrasound transducer was at 10% when it was turned on, but to obtain the optimal 
flow it was raised to 100% for the duration of the trial. The depth of the MCA is usually 
between 30-60mm deep if imaged from the temporal window.105 The use of the audible sound 
signal was used to distinguish between different cerebral vessels, as the MCA emits a higher-
pitched sound compared to the posterior cerebral artery.106 Flow direction of the MCA was 
towards the probe (visualised as red). If the insonated vessel was deeper than 70mm, and was 
still flowing towards the probe it was deemed likely to be the posterior cerebral artery,107 and 
the probe was readjusted in order to find the MCA. Once the optimal signal was obtained, the 
probe was tightened onto the headpiece so the signal would not be disturbed when the 
participant later performed the Valsalva manoeuvre. Participants were asked to remain still for 
5 minutes while the baseline test was conducted.  
 
The next stage involved the participants performing the Valsalva manoeuvre by blowing into 
a calibrated sphygmomanometer. A nose piece was put on them, and they were asked to take a 
large breath in, and then to blow out into the mouth piece maintaining 40 mmHg on the 
sphygmomanometer that they could see. They were asked to hold this exhalation for 10-15 
seconds maintaining it at 40 mmHg. If the Valsalva manoeuvre was unsuccessful, the 
participants were asked to rest for 2 minutes before trying again to allow for the cerebral 
velocity measures to normalise. The TCD device (Spencer Doppler ST3, model PMD150, 
Redmond, WA, USA) was attached to an analogue-to-digital converter (Powerlab, 
ADInstruments, Dunedin, NZ). This was interfaced to a personal computer running specialised 
research software (Labchart 8, ADInstruments, Dunedin, NZ) for data collection and storage 
at a sampling frequency of 1 kHz for later analysis. The MCA flow velocity envelope was 
collected during the 5 minute baseline period, and across the Valsalva manoeuvre. The data 
measured included the mean (which was obtained by integrating the waveform across the entire 
cardiac cycle), systolic and diastolic MCA flow velocities. For the baseline test, the last 2 
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minutes of the 5 minute baseline period was analysed. Additionally, the lowest (for phase 2) 
and highest (for phase 4) beat were measured during the Valsalva manoeuvre. 
 
Reliability Statistics 
Reliability was conducted in order to determine the reproducibility of my ability to insonate 
the MCA over several different trials in five participants. A paired two tailed t-test was 
completed to test for differences between trials 1 and 2 using Excel 2016. No formal statistics 
were carried out investigating differences across all three trials as only 2/5 participants 
completed all three trials which resulted in inadequate statistical power to complete a repeated 
measured ANOVA. Additionally, a consecutive pairwise test from the analysis of reliability 
template by Hopkins (2015) was used to estimate the reproducibility.108 The intraclass 
correlation coefficient (ICC), Pearson correlation coefficient, and the coefficient of variation 
were used to help determine the reliability.108 Reliability testing was calculated between trials 
1 and 2, and between trials 1, 2, and 3. 
 
Valsalva Manoeuvre 
The Valsalva manoeuvre was initially going to be performed by the patients using a calibrated 
device. However, in the first case study the patient blew against the device as instructed but 
the clinician indicated that the TTE image was distorted due to inflated lungs. Following this 
the decision was made to exclude the use of the calibrated device as a method of Valsalva 
manoeuvre for the remainder of the study. The standard Valsalva manoeuvre used by clinicians 
was then applied for the continuation of that case study. This involved a verbal prompt to bear 
down and force exhalation against a closed glottis or thumb in mouth, and was used for the rest 




• Echocardiography was performed by a sonographer using standard echocardiographic 
machines (Vivid S6, E9 or E95, GE Ultrasound or SC2000Prime, Siemens Ultrasound). 
Images were recorded according to the recommendations of the American Society of 
Echocardiography. Views for left ventricular (LV) and left atrial (LA) assessment included 
the apical 4-chamber, apical 2-chamber, apical long axis and short-axis views. Images of 
the right ventricle (RV) and right atrium (RA) were recorded in the apical 4-chamber view. 
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• Saline was injected into the arm using a three-way tap, and two syringes of saline. In the 
three way tap the saline was mixed with a little bit of drawn up blood (1ml) to agitate the 
saline for optimal imaging. This approach was consistent for all participants. 
• Following the injection of the agitated saline, the heart was continuously imaged and 
recorded as the patient performed the Valsalva manoeuvre.  
• A PFO was positively identified on TTE if a bubble, or bubbles were seen in the left atrium 
or left ventricle and were graded as follows: mild (<10 microbubbles), moderate (10-20 
microbubbles), or severe (>20 microbubbles) 
 
Transcranial Doppler 
• In most cases, a routine echo had already taken place, or a PFO was suspected, so the 
sonographer proceeded straight to a bubble study. Seeing as the patient had already given 
consent prior to this stage, I gave a brief re-explanation of the TCD procedure as I put the 
device on. The TCD device was set up and put on the same way as it was for the participants 
in the reliability study, and I used the probe to secure an optimal signal of the MCA. In 
some cases, it was harder than others and I had to ask for help from my supervisor to get a 
clear signal. 
• Just prior to the injection of the agitated saline contrast, the record button was pressed on 
the TCD device. The patient was then asked to perform the Valsalva manoeuvre which was 
considered effective when there was a peak Doppler flow velocity reduction > 25% in the 
MCA. Once all necessary tests were made the TCD was turned off and the probe and 
headband were unattached and removed from the patient, who was then given a tissue to 
remove the gel. The TCD device was then packed up and removed from the room swiftly 
for sterilization and preparation before the next patient.  
• The pulsed wave M-mode on the TCD device was used to assess the PFO and subsequent 
shunt in patients. The sweep settings were set on 4 seconds per frame. The TCD machine 
recorded both visual and audio recordings following the saline injection, and Valsalva 
manoeuvre. The presence of a microbubble could be visualised as a brightly coloured 
embolic track as it passed through the MCA. The PFO was graded as followed: grade 1 (1 
– 10 microbubbles), 2 (11 – 30 microbubbles), 3 (31 – 100 microbubbles), 4 (101 – 300 





No patients in this study had a TOE in the time period of this study, either due to COVID-19, 
or because it was not clinically indicated. 
 
RoPE Score 
The Risk of Paradoxical Embolism (RoPE) score (Table 1, page 4) is used in patients with 
suspected cryptogenic stroke which are positive for PFO, to determine the probability of the 
CS being due to a PFO, and how likely recurrence is (whether through a PFO or due to another 
unrelated cause).31 It was developed in 2013 by Kent et al., and was applied to all three case 




The middle cerebral artery blood velocities (MCAv) for the baseline, phase 2, and phase 4 
measurements for the five participants is presented in Table 4. The t-test showed that the 
systolic, mean and diastolic MCAv (cerebral artery blood velocity) did not significantly differ 
between trial 1 and trial 2 (p  ≥ 0.41). The reliability during baseline and in response to the 
Valsalva manoeuvre is presented for the five participants on Table 5 (for trials 1 and 2), and 
Table 6 (for trials 1, 2, and 3). The ICC is moderate throughout the baseline activity of all 
measurements (systolic MCAv, Mean MCAv, and Diastolic MCAv) when trials 1 and 2 are 
just compared, and when trial 3 is included (ICC ranges from 0.72 to 0.87). Cicchtti et al., 
indicates that an ICC of over 0.7 is indicative of internal consistency for research.109 The 
coefficient of variation is satisfactory for all results over all trials, indicating satisfactory 







Table 4: Middle cerebral artery flow velocities for each trial conducted for baseline, phase 2 and phase 4. 
CONDITION   TRIAL 1 TRIAL 2 TRIAL 3 

















BASELINE 1 73 45 32 80 47 33 90 52 38 
BASELINE 2 102 68 49 82 54 38 97 64 46 
BASELINE 3 90 61 44 95 63 43 
   
BASELINE 4 91 61 45 92 60 43 
   
BASELINE 5 103 65 47 109 71 52 
   
           
PHASE 2 LOWEST BEAT  1 60 37 28 74 41 29 73 44 35 
PHASE 2 LOWEST BEAT 2 84 47 32 75 41 27 74 45 36 
PHASE 2 LOWEST BEAT 3 75 49 39 82 56 44 
   
PHASE 2 LOWEST BEAT 4 97 58 43 84 47 35 
   
PHASE 2 LOWEST BEAT 5 85 52 35 75 40 32 
   
           
PHASE 4 HIGHEST BEAT 1 81 60 46 94 68 50 110 59 47 
PHASE 4 HIGHEST BEAT 2 103 80 66 106 81 63 84 66 53 
PHASE 4 HIGHEST BEAT 3 105 75 55 111 78 55 
   
PHASE 4 HIGHEST BEAT 4 103 66 43 92 71 59 
   
PHASE 4 HIGHEST BEAT 5 122 80 59 101 65 47 
   
Legend 4: Abbreviations, MCAv = Middle cerebral artery velocity
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Table 5: Reliability Results between trials 1 and 2 
RESULTS USING  
TRIALS 1-2 
 
ICC PEARSONS COEFFICIENT OF 
VARIATION 
BASELINE Systolic MCAv 0.74 0.64 12.9% 
  Mean MCAv 0.82 0.73 15.10% 
  Diastolic MCAv 0.82 0.73 16.10% 
          
PHASE 2 Systolic MCAv 0.47 0.63 13.00% 
  Mean MCAv 0.41 0.35 15.50% 
  Diastolic MCAv 0.85 0.77 18.20% 
          
PHASE 4 Systolic MCAv 0.46 0.45 11.50% 
  Mean MCAv 0.5 0.44 10.90% 
  Diastolic MCAv 0.29 0.26 14.90% 
Legend 5: Baseline measurement was taken over the last 2 minutes of the 5 minute baseline period. Phase 2 measured the 
lowest beat, while phase 4 measured the highest beat during the Valsalva Manoeuvre. Abbreviations: ICC = intraclass 
correlation coefficient, MCAv = middle cerebeal artery velocity 
 
Table 6: Reliability Results between trials 1, 2 and 3 
RESULTS USING TRIALS 
1, 2 & 3 (MEAN ICC) 
 
ICC PEARSONS COEFFICIENT OF 
VARIATION 
BASELINE Systolic MCAv 0.78 0.64 12.30% 
  Mean MCAv 0.87 0.73 15.10% 
  Diastolic MCAv 0.87 0.73 15.80% 
          
PHASE 2 Systolic MCAv 0.55 0.63 12.40% 
  Mean MCAv 0.51 0.35 14.70% 
  Diastolic MCAv 0.87 0.77 17.10% 
          
PHASE 4 Systolic MCAv 0.12 0.45 12.50% 
  Mean MCAv 0.58 0.44 10.80% 
  Diastolic MCAv 0.38 0.26 14.50% 
Legend 6: Baseline measurement was taken over the last 2 minutes of the 5 minute baseline period. Phase 2 measured the 
lowest beat, while phase 4 measured the highest beat during the Valsalva Manoeuvre. Abbreviations: ICC = intraclass 
correlation coefficient, MCAv = middle cerebeal artery velocity 
 
Case Study Results 
Due to COVID-19, this study only managed to recruit 3 patients prior to the hospital being 
closed to non-essential users. The attributes and results of each of these case studies will be 




Table 7: Characteristics, findings and decisions of the three case studies in the present study 
 CASE 1 CASE 2 CASE 3 
AGE (YEARS) 55 61 52 
SEX Female Male Female 
HEIGHT (CMS) 164cm 174cm 157cm 









symptoms and collapse 
HYPERTENSION Yes – on Losartan 25mg No Yes 
DIABETIC No No Yes 
SMOKER No No Yes 
OTHER RISK 
FACTORS 
Dyslipidaemia – on 
Atorvastatin 10 mg 
Dyslipidaemia – on 
Atorvastatin 40 mg  
Overweight 
Family history of 
myocardial infarction 
Dyslipidaemia – on 
Atorvastatin 20 mg  
Overweight 
Obstructive Sleep 
apnoea on CPAP 
ROPE SCORE 5 5 3 
ECG FINDINGS No abnormal findings 
 
No abnormal findings 
 
Ventricular Trigeminy 
on presentation but 
reverted back to 





No LV systolic 
dysfunction 
EF 55-60% 
Mildly dilated LA 
TAPSE 2.5cm 
No abnormal findings 
EF 55% 






inferior lateral and 
possible anterior) 
PFO YES/NO Yes Yes Yes 
TTE RESULT Mild shunt Severe shunt Severe shunt 
TCD RESULT Grade 1 (mild shunt) Grade 5 (severe) N/A 
DECISION PFO incidental finding PFO closure using 
amplatzer 
PFO incidental fining 
Legend 7: PFO = patent foramen ovale, CPAP = continuous positive airway pressure, LV = left ventricle, LA = left atrium, 
EF = ejection fraction, TAPSE = tricuspid annular plane systolic excursion. 
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Case Study #1 
This 55 year old female patient who was of NZ/European ethnicity arrived to the 
echocardiography laboratory as an outpatient who had experienced multiple neurological 
symptoms and chest pain. A bubble study was conducted to assess possibility of CS through a 
PFO. The patient had no history of smoking and did not have diabetes. Losartan 25 mg was 
being used to treat hypertension, and Atorvastatin 10 mg was being used to treat dyslipidaemia. 
The echocardiogram revealed an ejection fraction (EF) of 55-60%, a mildly dilated LA, and 
normal RV size and function. The tricuspid annular plane systolic excursion (TAPSE), which 
is a parameter of global RV function, was normal at 2.5cm, and the RV systolic pressure was 
normal at 22mmHg+RA (about 5mmHg). The RoPE score for this patient, if a CS was found 
to be the cause of dysfunction, was 5. It took a few minutes to locate the MCA and secure a 
strong signal using the TCD. Initially the sphygmomanometer was used for the provocation of 
the Valsalva manoeuvre, but after the first attempt the clinician in charge of the TTE observed 
inflated lungs which obstructed the image of the TTE. From there a non-calibrated Valsalva 
manoeuvre was used. The aortic arch was imaged for the presence of microbubbles with none 
seen. TCD showed the passage of a small number of potential microbubbles and graded the 
shunt a 1 (1 – 10 microbubbles) (Fig. 7A). TTE also showed the passage of microbubbles into 
the LA and LV, and the shunt was classed as mild (<10 microbubbles) by the clinician using 
the TTE grading scale (Fig. 7B). Later on, the patient underwent a structural magnetic 
resonance imaging (MRI) to identify the presence/absence of a cortical infarct, none of which 
was found. The PFO was then later deemed to be an incidental finding as there was no stroke 












7. TCD and TTE in Case 1 
 
Figure 7: (A) TCD of the middle cerebral artery, arrow points at a potential microbubble travelling through the artery. (B) 
TTE of the heart (apical 4-chamber view), arrow indicates a microbubble in the LV, indicating the presence of a PFO. 
Abbreviations: TCD = transcranial Doppler, TTE = transthoracic echocardiogram, LV = left ventricle, PFO = patent foramen 
ovale. 
Case Study #2 
This 61 year old male who was of NZ/European ethnicity arrived to the echocardiography 
laboratory as an outpatient after an ischemic stroke. A bubble study was undertaken to assess 
for the presence of a PFO. The patient had family history of myocardial infarction, and was 
overweight. Atorvastatin 40mg was being used to treat dyslipidaemia. The patient did not have 
hypertension, had no history of smoking, and did not have diabetes. The structural 
echocardiogram revealed an EF of 55%, a mildly dilated LA, and normal RV size and function. 
The TAPSE was normal at 2.7cm, and the RV systolic pressure could not be assessed, but 
appeared normal. This patient had a RoPE score of 5, which indicated a 34% chance of the 
stroke being due to a PFO, and a 7% chance of a similar recurrent event. A subcostal view 
using colour Doppler of the interatrial septum displayed movement of venous blood from the 
RA to the LA, presumably through a PFO (Fig. 8). During one of the contrast injections the 
clinician used abdominal compression to provoke a Valsalva manoeuvre, which improved the 
sensitivity of both techniques compared to a normal Valsalva manoeuvre (Fig. 9 and 10). TTE 
showed the passage of microbubbles into the LA and LV during normal Valsalva manoeuvre 
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and when abdominal compression was applied during the Valsalva manoeuvre, and the shunt 
was classed as severe (>20 microbubbles) by the cardiologist using the TTE grading scale (Fig. 
9A and 9B). TCD indicated the presence of a grade 2 PFO (11 – 30 microbubbles) during the 
normal Valsalva manoeuvre (Fig. 10A), but demonstrated a grade 5 PFO (shower curtain, >300 
microbubbles) when abdominal compression was applied (Fig. 10B) The aortic arch was also 
visualised for the presence of any microbubbles travelling to the periphery, and 2 microbubbles 
were detected travelling down the aortic arch. This patient was referred on for AMPLATZER 
closure of PFO which was occluded (25mm) successfully. TOE was not used to assess or 
confirm the presence of a PFO prior to this.  
8. TTE of the IAS in Case 2 
 
Figure 8: Subcostal view using TTE of the IAS, where venous blood (blue) can be seen travelling from the RA into the LA, and 
mixing with arterial blood (red). Abbreviations: TTE = transthoracic echocardiography, IAS = interatrial septum, RA = right 











9. TTE in Case 2 
 
Figure 9: TTE of the heart during (A) normal Valsalva manoeuvre, (B) Valsalva manoeuvre with abdominal compression. 
Abbreviations: TTE = transthoracic echocardiography 
 
10. TCD in Case 2 
 
Figure 10: TCD imaging of the middle cerebral artery. (A) Microbubbles visible during normal Valsalva manoeuvre, (B) 
Shower 'curtain' of microbubbles observed during abdominal compression paired with the Valsalva manoeuvre. 




Case Study #3 
This 52 year old female who was of NZ/European ethnicity arrived at the echocardiography 
laboratory as an inpatient with neurological symptoms and collapse. The previously conducted 
computerised tomography (CT) scan and MRI showed no relevant abnormalities but a PFO 
was still suspected. The patient had hypertension, and diabetes, was a smoker, and was 
overweight. The patient also had obstructive sleep apnoea which was being treated with 
continuous positive airways pressure (CPAP). Atorvastatin 20mg was being used to treat 
dyslipidaemia. The echocardiogram revealed an EF of 45-50%, and the patient appeared to 
have wall motion abnormalities (inferior, inferior lateral and possible anterior). The RoPE 
score for this patient, if a CS was found to be the cause of dysfunction, was 3. No cerebral 
vessel velocity signals could be found, which was likely to be due to a poor temporal bone 
window. TCD was therefore unsuccessful in this patient. TTE showed the passage of 
microbubbles into the LA and LV at both rest (Fig. 11A) and during the Valsalva manoeuvre 
(Fig. 11B), and the shunt was classed as severe (>20 microbubbles) using the TTE grading 
scale. The aortic arch was imaged and several microbubbles were seen travelling to the 
periphery (Fig. 12). The PFO was then later deemed to be an incidental finding as there was 
infarct on the MRI, and the symptoms the patient presented with were likely to have been 
caused by a separate risk factor (such as hypertension).  
11. TTE in Case 3 
 
Figure 11: Transthoracic echocardiogram of the heart. (A) Arrow indicates microbubbles in the left ventricle at rest, (B) 





12. TTE of the Aortic Arch in Case 3 
 
Figure 12: View of the aortic arch using TTE. The arrow indicate the microbubble as it travels through the arch, past the left 
carotid artery and subclavian artery, before travelling down to the periphery. Abbreviations: TTE = transthoracic 




The reliability testing demonstrated the reliable insonation of the MCA in the same participants 
over a series of trials. This allows us to assume that the arteries insonated in the present study 
are correct and accurate. The ICC indicates the ‘relative reliability’, and estimates the 
consistency of multiple measurements taken on separate occasions in an individual.110 The 
coefficient of variance is an indicator of the amount of error associated with those multiple 
measures, and indicates the absolute reliability.111 These assessments were made to ensure that 
any variance within the data comes from between the participants, not between the variables 
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measured (i.e. the MCA of one participant may be deeper than the MCA of the other, so this 
testing would indicate differences between separate tests on the same participants, not between 
participants). The ICC for the baseline measurements was satisfactory, indicating satisfactory 
reproducibility. However, the ICC is reduced during phase 2 and phase 4 compared to baseline 
in both sets of results over all measurements, which is likely to be due to differences in the 
Valsalva manoeuvre. The Valsalva manoeuvre is a dynamic physiological response, and 
therefore it commonly has a variable physiological response associated with it. Additionally, 
patients often contract their head muscles when performing the Valsalva manoeuvre which can 
disturb the flow signal and subsequent velocity value. Despite the more moderate ICC over the 
Valsalva manoeuvre, it still indicates the ability to maintain a good quality velocity signal 
across and following a Valsalva manoeuvre which is critical for the detection of microbubbles 
if a right-to-left shunt (RLS) is present. Lastly, the ICC appeared to increase over all of the 
measurements when comparing results from just trials 1 and 2, to trials 1, 2, and 3. This is 
indicative that the ICC would have continued to improve should all trials have occurred three 
times as planned.  
 
Similarities between the Cases 
The prevalence of a PFO in CS patients is higher than that of the general population (40% vs 
25%),26 especially in young (<55 years) CS patients (up to 55%).88 We report three patients 
with suspected CS or confirmed ischemic stroke who were referred on to the cardiology 
department for a bubble study for investigation of a possible PFO. Despite the similarity in age 
(ranges from 52 to 61 years), the three patients had varying risk-factors and pre-existing health 
conditions (see Table 7). All three patients were found to have a PFO, and both TTE and TCD 
were in eventual agreement with the determination of shunt severity in all patients, except case 
3 where TCD was unsuccessful due to an absent temporal bone window. 
 
The degree of shunt determination in case 1 was relatively consistent between TTE and TCD, 
with both methods grading the shunt as mild from their respective shunt grades. While this 
consistency is positive, studies have shown that smaller shunts are often indicative of an 
‘innocent shunt’ that poses no further threat.13 This was later confirmed when the MRI showed 
no cortical infarct, and the PFO was deemed to be an incidental finding. Case 1 had a RoPE 
score of 5, indicating a 34% chance of the presenting condition to be due to PFO, and a 7% 
chance of general recurrence. Although case 1 did not end up presenting with a infarct on 
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imaging, this reinforces the importance of the RoPE score and how it may shape the decisions 
the clinician makes in terms of discovering a potentially innocent PFO vs a potentially 
dangerous PFO, and how to go forward with treatment.94  
 
Studies have shown that a RoPE score of above 7 is highly indicative of the PFO being causal 
to the CS.32 However, other studies have indicated that a lower rope score (1-7) is related to an 
increased chance of recurrence compared to a RoPE score of >7 (12.9% vs 5.4% respectively), 
especially in patients that present with a transient ischemic attack (TIA).95 This is thought to 
be due to other present risk factors for stroke being more likely to cause embolism compared 
to a RLS through a PFO.94 While the RoPE score for patient 2 was also 5 (regarded as a low 
RoPE score), the shunt was classed as severe. Since the patient presented with ischemic stroke 
on MRI, and demonstrated a large RLS using both methods, as well as when imaging the 
interatrial septum, the decision to close the PFO was made. When compared to case 3, who 
also had a severe shunt diagnosed by TTE, case 2 presented with less risk factors that may have 
attributed to the initial event, therefore making the case for closure much more compelling. 
While case 3 still presented with a large RLS, the RoPE score was 3, and the pre-existing health 
conditions (i.e. was a smoker, had diabetes and hypertension) meant the chances of the PFO 
being causal to the CS were unlikely. It also indicated that the chances of recurrent stroke 
through a mechanism unrelated to a PFO were much more likely, and therefore the closure of 
the PFO was unlikely to make a difference.  
 
While the RoPE score is relatively new and is still being applied in up-and-coming studies, its 
relevance in this present clinical study is high as it indicates the importance of a correct and 
accurate PFO diagnosis. If TTE and TCD are not correctly identifying the attributes of a PFO, 
the subsequent decisions made by the clinician may not be the most suitable for the patient. 
This highlights the need for further investigation into what may be the optimal method of PFO 
diagnosis, and the exposure of the pitfalls and advantages of each technique so they can be 
adapted to appropriately.  
 
Challenges of both Techniques 
All three cases exposed both positive and negative attributes of TTE and TCD. While case 1 
was the most consistent in terms of grading the severity of the PFO, TTE was impaired by 
inflated lungs when the sphygmomanometer was used to provoke the Valsalva manoeuvre. 
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TTE can be impaired by over inflation of the lungs in a patient, due to them taking too large of 
a breath in prior to the Valsalva manoeuvre,86 as may have been the case in this particular 
patient. Some studies have shown that the sphygmomanometer is a good method of provoking 
a change in interatrial pressure to mimic the Valsalva manoeuvre,112 but other studies have 
criticised it.52 When using a sphygmomanometer the patient is required to maintain a 40mmHg 
pressure. However, it is impossible to know whether that is being maintained by palatal closure 
or elevated intrathoracic pressure.52 In this particular case the inflated lungs was likely to have 
been caused by exaggerated inspiration prior to the patient using the sphygmomanometer, 
which did not affect TCD and its ability to grade the shunt. However, if the Valsalva manoeuvre 
was not able to prompt a proper change in intrathoracic pressure, this would have affected both 
TTE and TCD as the chances of microbubbles shunting through the PFO were much less likely. 
More research into the use of a sphygmomanometer is needed in order to establish its 
application in a clinical setting. 
 
Prior to abdominal compression, case 2 was graded as severe using TTE, but only as mild using 
TCD. This is directly indicative of how the two grading scales are not aligned. While a severe 
shunt using TTE only requires more than 20 bubbles to be visualised in the left heart, a severe 
shunt using TCD (i.e. grade 4 or 5) requires more than 100 microbubbles to travel through the 
MCA. In case 2, around 25 microbubbles were seen using both methods during the normal 
Valsalva manoeuvre, but the shunts were graded on opposing ends of the spectrum. However, 
when abdominal compression was used, the grade of TTE did not change (as it was already 
classed as the highest grade prior to compression), but the TCD grade escalated to a grade 5 
shunt. This indicates the importance of a proper Valsalva manoeuvre to give the most accurate 
indication of grade as possible, and highlights a potential downfall of TTE as the threshold for 
a ‘severe’ shunt is relatively low.   
 
Case 3 exposed one of the major pitfalls of TCD as we were not able to locate the MCA. TTE 
imaged the heart without problems and indicated the presence of a severe shunt. Studies have 
shown that the absence of a temporal bone window is more common in females than males 
(females 67% vs males 35% in patients with an absent temporal bone window),113 and is 
believed to be present in about 10% of individuals.80 Alternatives such as the transorbital 
approach,90 or submandibular approach114 can be utilised, however this had not been practiced 
by myself, or had undergone reliability testing prior to the commencement of this study, and 




Alternative Imaging planes, Peripheral Emboli 
Microbubbles travelling to the periphery were seen in both case 2 and 3. Imaging the aortic 
arch is a novel technique used in this study to investigate the presence of microbubbles 
travelling to areas other than the brain. TTE is able to directly image these microbubbles in the 
aortic arch itself. TCD is unable to do this as any microbubbles visible in the MCA have already 
deviated from the arch and travelled upstream. Microbubbles travelling downstream after a 
RLS through a PFO poses a threat to other areas of the body such as the kidney and limbs.115 
The ability of TTE to image these bubbles directly is a major advantage over TCD, and 
although the presence of microbubbles in the MCA using TCD could assume the presence of 
microbubbles in the aortic arch as well, the direct visualisation of such is superior. Above all, 
imaging emboli as they move from the ascending aorta and down the descending aorta could 
potentially offer a diagnostic advantage for peripheral embolism and could be the focus of 
future work.   
 
Limitations 
None of the cases in the present study were referred on for a TOE. This was understandable in 
case 1 and 3 where the PFO was deemed to be an incidental finding and was less likely to cause 
further complications. However, case 2 did not undergo a TOE prior to closure. The use of 
TOE is common prior to the closure of a PFO, as it is used to assess and measure the area for 
the suitability of closure, and to ensure the right sized device is used. However, the decision 
not to go forward with a TOE was likely impacted by COVID-19. During the pandemic most 
patients that required a TOE were either rebooked or reconsidered due to the risk of an aerosol 
generating procedure, which would have put both the patients and clinicians at risk. As such, 
we were unable to compare TTE and TCD to a reference technique, and could not compare all 
three techniques within the same patient to determine if any of the methods had provided false 
negative or false positive results. Moreover, sensitivity and specificity are best calculated when 
matched against a reference technique, so the present study would have carried more 
significance were the TTE and TCD weighed against TOE. In regards to reproducibility, it 
would have been best to complete all three trials in all five reliability participants, but due to 
COVID-19 that was not possible. However, the presenting results give a satisfactory indication 





To summarise, the three case studies all displayed the presence of a RLS through a PFO. The 
largest shunt was successfully closed, and the other two shunts were determined to be 
incidental findings that were unlikely to cause future recurrent events. TTE was able to 
diagnose all three shunts as positive, as well as image the aortic arch, but struggled when a 
sphygmomanometer was used to prompt a Valsalva manoeuvre due to inflated lungs. TCD 
gave a precise shunt grade for two of the three cases, but was not able to grade the third due to 
an insufficient temporal bone window. TTE and TCD differed in their grading of the normally 
provoked shunt in case 2, indicating that the two grading systems may not be perfectly aligned. 
However, they were well matched when abdominal compression was used to provoke the 
Valsalva manoeuvre. A larger scale study is needed comparing TTE to TCD in CS patients, or 
patients presenting with the symptoms of a CS. The use of TOE as a reference technique would 
also shed light on each technique and indicate the presence of any false positive or false 
negative results. The RoPE score should be used and critiqued as we further understand how 
well it is aligned with clinicians and the choices they make regarding the contribution of the 
PFO to the presenting symptoms, as well as the likelihood of it causing recurrence. A follow 
up period of several years would be beneficial as this would enable the assessment of success 
of treatment (if taken) and recurrence in relation to PFO presence.  
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Chapter Three: Systematic Review 
and Meta-analysis 
Introduction 
Thus far in the present thesis, we have discussed a patent foramen ovale (PFO), its prevalence, 
and ischemic events it can contribute to such as cryptogenic stroke (CS) and migraine. We have 
reviewed the three primary methods of PFO diagnosis; transthoracic echocardiography (TTE), 
transcranial Doppler (TCD), and transoesophageal echocardiography (TOE) and their use in 
current literature, as well as their pitfalls and advantages. Additionally, we have applied the 
two bedside techniques to a group of case studies in a clinical application to directly assess 
their diagnostic ability in patients with ischemic stroke or suspected CS. The case studies 
uncovered both advantages and pitfalls of TTE and TCD, further adding to the conversation 
comparing these two techniques in current literature. The presence of a right-to-left shunt 
(RLS) through a PFO is associated with CS, a type of stroke that has an unknown source of 
embolism and therefore the cause of the stroke-like symptoms is unknown.5 The association 
between PFO and CS is still under debate,94,116,117 as well as the methods used to diagnose a 
PFO.85 While the general level of sensitivity and specificity of TTE and TCD is high, studies 
comparing both techniques against a gold standard reference technique (TOE) indicate there is 
still inconsistency between TTE and TCD in regards to the optimal techique.48,69,81,82 Meta-
analyses have been conducted that compare TTE to TOE,78 and others that compare TCD to 
TOE.79 If these two meta-analyses are compared side to side, TCD appears to be the most 
sensitive technique, while TTE the more specific. Katsanos et al., conducted a meta-analysis 
which compared different studies using TTE or TCD alongside the reference technique TOE, 
and came to the same conclusion.93 While the results of these meta-analyses draw the same 
generalised conclusion, they do not consider studies where TTE and TCD were performed in 
the same cohort of patients making a direct comparison between TCD and TTE impossible. 
The present systematic review and meta-analysis will analyse studies using TTE and TCD in 
the same cohort of patients with or without a reference technique. This will shed light on the 
current status of TTE and TCD and their abilities to make the most accurate diagnosis in the 
same group of patients, with the same presenting symptoms and risk factors, and investigate 
the effect that TOE has on the diagnostic ability of either technique when introduced as a 
reference standard. This systematic review and meta-analysis will include studies that assess 
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patients with possible CS or migraine-like symptoms that are therefore undergoing a bubble 
study for PFO presence. 
 
Rationale 
There is inconsistency within the literature regarding the optimal test for PFO diagnosis. TTE 
and TCD are often used interchangeably between different studies, with or without a gold 
standard measurement of reference (TOE). It is obvious that there is a relationship between 
PFO presence and CS or migraine, especially in the younger population (<55 years).30 However 
it is still debated as to whether or not the relationship is causal.30,52 Therapeutic remedies to 
treat a PFO have shown to decrease the prevalence of ongoing problems,118 as well as reduce 
the chance of recurrent events,21 so the accurate diagnosis and assessment of a PFO is crucial. 
This meta-analysis will review the previous literature involving the use of TTE, and TCD to 
diagnose a PFO in CS patients or migraine patients predominantly. It will include studies with 
or without TOE used as a gold standard. This meta-analysis will be conducted to help determine 
the current ability of these diagnostic techniques and gain insight as to which technique may 
have the upper hand for PFO diagnosis.  
 
Methods 
The present meta-analysis adhered to the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines,119 and was developed according to the MOOSE 
(Meta-analysis of Observational Studies in Epidemiology) proposal.120  
 
Eligibility Criteria 
Studies involving patients with stroke or migraine as the main aetiology were included.  Studies 
included required to have both TTE and TCD performed on the same cohort of human 
participants, and preferably a gold standard test for confirmation (i.e. TOE). These studies were 
graded as A quality. Studies that included TTE and TCD without external confirmation (i.e. no 
TOE) were included but graded as B quality. Studies were excluded if they recruited children 
or had less than 20 participants. This was because studies with a larger cohort of participants 
were a more reliable source of statistical significance in terms of pooled sensitivity and 
specificity. Additionally, there were no studies with under 20 participants, other than case 
studies, that made the inclusion criteria as they were excluded for other reasons. If a study 
involved a control group, the results from this group were omitted. If this was not possible the 
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study was omitted. Control groups were omitted as the study was focused on the assessment of 
a PFO due to a suspected CS, and the accuracy of the assessment techniques. Additionally, the 
controls were excluded to keep the data extraction consistent as only one of the final studies 
included involved controls. 
 
Information Sources 
Online databases were used to yield all results. This included Web of Science, Scopus, 
PubMed, and Medline/Ovid. 
 
Search Strategy 
This study used an advanced Boolean search strategy in all databases and identified all studies 
before March 7, 2020, no limit was applied to the start date. This involved the following 
phrases: ("Echocardiography" OR "Doppler" OR "TTE" OR "transthoracic echocardiography" 
OR "transthoracic echocardiogram" OR "ultrasound" OR "TOE" OR "transoesophageal 
echocardiogram" OR "transoesophageal echocardiography"), ("TCD" OR "transcranial 
doppler" OR "doppler"), ("PFO" OR "patent foramen ovale" OR "RLS" OR "right-to-left shunt 
OR ASD" OR "Atrial septal defect"), ("Stroke" OR "cryptogenic stroke" OR "TIA" OR 
"transient ischemic attack" OR "cerebrovascular event" OR "ischemic stroke" OR "cerebral 
ischemia" OR "peripheral emboli" OR "paradoxical embolism"). Hits from all databases were 
included, and duplicates were removed. References of selected studies were also searched 
manually for articles that may have been missed in the initial search. No language restrictions 
were imposed at any stage of the selection. 
 
Selection Process 
After duplicates were removed, titles and abstracts were screened by three reviewers (myself 
(HVDG), supervisor (GAW), and supervisor (LW)). Studies read in full if 2/3 reviewers agreed 
that the title or abstract included the use of either TTE or TCD as a screening method for the 
detection of RLS or indicated the potential for the use of either technique. The final set of 
studies to be read in full were assessed by three reviewers (HVDG, GAW, and LW) and were 
included for extraction if 2/3 reviewers agreed that the study mentioned the use of both 




Data Extraction Process 
Data was extracted from eligible studies by two reviewers (HVDG and GAW) and any 
disagreements were resolved by consensus (HVDG, GAW, and LW). The data extracted from 
each study included first author, year of publication, country, main aetiology, mean age (years), 
number of subjects, proportion of females, proportion of subjects with PFO, and the true 
positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity, and 
specificity of each technique (TTE and TCD). The methodological quality of each paper was 
graded with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.121 
 
Risk of Bias 
Studies were assessed for all forms of bias by 2/3 reviewers (HVDG and GAW). It was agreed 
upon that because this meta-analysis was investigating the diagnostic ability of the detection 
methods, not the prevalence of PFO in the population, selection bias would be present. To 
ensure that studies evaluated patients in a consecutive fashion, we assessed for red flags such 
as an extremely high prevalence of PFO in the cohort, as this would indicate only patients with 
a PFO were evaluated, not patients with a suspected PFO. Additionally, studies were excluded 
if the use of the Valsalva manoeuvre was not consistent between patients or methods. This 
aimed to prevent a bias towards one technique over another (e.g. normal provocation of the 




The pooled sensitivity, specificity, as well a receiver operating characteristic (ROC) curve, 
with a 95% confidence interval (CI), were separately estimated for TCD and TTE. The A grade 
studies were calculated against TOE, which was treated as the gold standard, and the B grade 
studies were calculated against each other, with a positive TCD being presumed as true-positive 
unless stated otherwise. All statistical analyses were performed with Review Manager 
(Revman) version 5.3 software (Copenhagen, Denmark, Nordic Cochrane Centre, Cochrane 






The search strategy yielded 2108 articles, and after the deletion of duplicates 1146 studies 
remained for the first assessment (title + abstract). After the first assessment, 961 studies were 
excluded based on the title and abstract. One hundred and eighty five studies were then 
retrieved for full text review, of these 173 were excluded as they either did not have TTE and 
TCD (n=71), had incorrect methodology (e.g. was a case study, or had too smaller cohort) 
(n=53), had insufficient data (e.g. mentions the right methods, but is focused on another area 
so did not provide the right data to extract) (n=42), were biased (n=5), or other (n=2). Finally 
seven grade A studies,34,48,53,69,81,82,122 and five grade B studies123–127 were included (Fig. 13). 
13. PRISMA flow diagram of study selection 
 
Figure 13: Flow chart diagram presenting the selection of eligible studies. Grade A = A study that included both TTE and 
TCD as an imaging method, with TOE used as a gold standard in the same patients. Grade B = A study that only uses TTE 
and TCD as an imaging method in the same patients. Abbreviations: PRISMA = preferred reporting items for systematic 





The seven grade A studies included 537 patients (weighted average of 79% stroke/transient 
ischemic attack (TIA)), had a mean age of 51 years and was comprised of 51% females. The 
five grade B studies included 476 patients (weighted average of 75% stroke/TIA), had a mean 
age of 48 years and was comprised of 47% females. The characteristics of the included studies 
can be found on Table 8. 
Table 8: Characteristics of included studies in the Meta-Analysis 










Di Tullio et al81 1993 A 49 100 64 44 39 
Nemec et al82 1991 A 32 68 50 56 41 
Maffè et al69 2010 A 75 56 49 63 83 
Albert et al53 1997 A 69 100 44 59 36 
González-Alujas et al48 2011 A 134 89 46 44 69 
Zito et al34 2009 A 72 69 49 54 65 
Souteyrand et al122 2006 A 107 100 56 37 35 
Puledda et al127 2016 B 97 100 40 38 52 
Di Tullio et al123 1993 B 80 100 61 41 26 
Teague et al126 1991 B 46 52 41 46 41 
Itoh et al124 1994 B 30 100 55 40 57 
Corrado et al125 2011 B 232 22 43 69 77 
Legend 8: Grade A = A study that included both TTE and TCD as an imaging method, with TOE used as a gold standard in 
the same patients. Grade B = A study that only uses TTE and TCD as an imaging method in the same patients. Abbreviations: 
TTE = transthoracic echocardiogram, TCD = transcranial Doppler, TOE = transoesophageal echocardiogram, TIA = 
Transient Ischemic attack. 
Quality Assessment 
The quality assessment of included studies used the recommended 14-item checklist (Table 
9).121 Items 1, 2, 5, 6 and 7 scored well indicating the absence of bias in those areas. All items 
that are not depicted in green for “yes” are discussed in the legend other than items 12 and 13 
which were classed as “unclear” as they were unreported. Item 7 (“Was the reference standard 
 
 49 
independent of the index test (i.e. the index test did not form part of the reference standard)?”) 
was true and correct in all studies, although one could argue that the efficiency of the Valsalva 
manoeuvre could influence the diagnostic accuracy of each test, if conducted at different times. 
The use and provocation of the Valsalva manoeuvre tended to be inconsistent between studies. 
Some studies made patients practice the Valsalva manoeuvre prior to the assessment,125 others 
would only conduct it if no obvious PFO was seen at rest, and without prior practice.126 
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Table 9: The QUADAS 14 - point checklist for bias within included studies 
The QUADAS 14 – Point Checklist for 
Included Studies 
Di Tullio 



















a et al 
(B) 
Di Tullio 







o et al 
(B) 
1. Was the spectrum of patients representative of 
the patients who will receive the test in 
practice? 
            
2. Were selection criteria clearly described?               
3. Is the reference standard likely to correctly 
classify the target condition? 
** ** ** ** ** ** ** ** ** ** ** ** 
4. Is the time period between reference standard 
and index test short enough to be reasonably 
sure that the target condition did not change 
between the two tests? 
   †   †      
5. Did the whole sample or a random selection of 
the sample, receive verification using a 
reference standard of diagnosis? 
            
6. Did patients receive the same reference 
standard regardless of the index test result?  
            
7. Was the reference standard independent of the 
index test (i.e. the index test did not form part 
of the reference standard)?  
            
8. Was the execution of the index test described in 
sufficient detail to permit replication of the 
test? 
           ‡ 
9. Was the execution of the reference standard 
described in sufficient detail to permit its 
replication? 
           ‡ 
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10. Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
 *       *   * 
11. Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
 *       *   * 
12. Were the same clinical data available when test 
results were interpreted as would be available 
when the test is used in practice? 
            
13. Were uninterpretable/ intermediate test results 
reported? 
            
14. Were withdrawals from the study explained?            × 
Legend 9: A = A grade study that included both TTE and TCD as an imaging method, with TOE used as a gold standard in the same patients. B = B grade study that only uses TTE and TCD as 
an imaging method in the same patients. Abbreviations: QUADAS = Quality Assessment of Diagnostic Accuracy Studies, TTE = transthoracic echocardiogram, TCD = transcranial Doppler, 
TOE = transoesophageal echocardiogram, TIA = Transient Ischemic attack. 
*  This study did not mention blinding of results, so it was unclear to if this was done or not.  
**  This question is subjective to current literature and drives the overarching theme of this review. While the Grade A studies have reasonable 
ground to consider transoesophageal echocardiography (TOE) as the reference standard, Grade B studies are comparing transthoracic 
echocardiography (TTE) to transcranial Doppler (TCD) both of which are not considered the current reference standard, so the answer for 
item 3 is unclear. 
†  The time period between tests was not mentioned.  
‡  The methods were not described in detail 
×  Nine patients did not have both methods (232 participants in study, full results for only 223 included in the analysis). Therefore, nine were 
unaccounted for.  
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Results of Grade A Studies 
The forest plot for the A grade studies, which included TTE and TCD as detection methods for 
PFO prevalence against the reference technique TOE, can be seen in Figure 14. Generally, 
specificity was high for both TCD and TTE across studies, ranging from 0.92 to 1.00 for TCD, 
and remaining at 1.00 for TTE. TCD gave the highest number of FP diagnoses compared to 
TTE (1.3% vs 0% respectively), but TTE reported the highest number of FN diagnoses (10.6% 
for TTE compared to 3.7% for TCD). Overall, both methods were more likely to produce a FN 
than a FP result. When the weighted specificity of the two techniques were compared in a 
summary forest plot, there was no difference: specificity for TCD was 0.97 (95% CI 0.94-0.99) 
and specificity for TTE was 1.00 (95% CI 0.98-1.00) (Fig. 15). When the weighted sensitivities 
were compared the sensitivity was significantly lower in the TTE (0.81, 95% CI 0.76-0.85) 
studies compared to TCD (0.91, 95% CI 0.86-0.94) (Fig. 14). There was a trend towards higher 
sensitivity with later year of publication for TTE, but not TCD (Fig. 15). The ROC curve was 
similar for both methods but favoured TCD overall (Fig. 16A). 
14. Forest plot of the Grade A studies 
 
Figure 14: Forest plot of the sensitivity and specificity of each individual grade A study. Grade A = A study that included both 
TTE and TCD as an imaging method, with TOE used as a gold standard in the same patients. Abbreviations: TTE = 
transthoracic echocardiogram, TCD = transcranial Doppler, TOE = transoesophageal echocardiogram, TP = true positive, 
FP = false positive, FN = false negative, TN = true negative, CI = confidence interval.  
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15. Summary Forest plot of Grade A and B studies 
 
Figure 15: Summary forest plot of the sensitivity and specificity of each grade A study and each grade B study, between TTE 
and TCD. Grade A = A study that included both TTE and TCD as an imaging method, with TOE used as a gold standard in 
the same patients. Grade B = A study that only uses TTE and TCD as an imaging method in the same patients. Abbreviations: 
TTE = transthoracic echocardiogram, TCD = transcranial Doppler, TOE = transoesophageal echocardiogram, TP = true 
positive, FP = false positive, FN = false negative, TN = true negative, CI = confidence interval.. 
16. ROC curve for A and B Grade studies 
 
Figure 16: ROC curve for studies graded as A and B. Sensitivity is on the Y axis, specificity is on the X axis. Grade A = A 
study that included both TTE and TCD as an imaging method, with TOE used as a gold standard in the same patients. Grade 
B = A study that only uses TTE and TCD as an imaging method in the same patients. Abbreviations: ROC = receiver operating 
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Results of Grade B Studies 
The forest plot for grade B studies that compared TTE and TCD without TOE as a reference 
standard can be seen in Figure 17. Since there was no reference standard, specificity was high 
(1.00) for both techniques across all studies. Additionally, the absence of a gold standard 
reference technique meant it was harder to decipher FN or FP results. If a technique diagnosed 
a patient as positive for PFO it was taken as a TP, and if the opposing technique failed to detect 
the PFO it was taken as a FN. With that in mind, neither technique had any false positives, but 
TCD gave the highest number of false negatives compared to TTE (10% vs. 7.5%). When the 
weighted sensitivity and specificity for the grade B studies was calculated, specificity was high 
for both TCD and TTE and there was no difference between the two techniques. Overall 
specificity for TCD was 1.00 (95% CI 0.98-1.00) and for TTE 1.00 (95% CI 0.98-1.00) (Fig. 
15). However, sensitivity was lower overall in the TCD (0.83, 95% CI 0.78-0.87) studies 
compared to the TTE (0.87, 95% CI 0.83-0.91) studies (Fig. 15). The ROC curve was similar 
for both methods but favoured TCD overall (Fig. 16B). 
17. Forest plot of the Grade B studies 
 
Figure 17: Forest plot of the sensitivity and specificity of each individual grade B study. Grade B = A study that only uses 
TTE and TCD as an imaging method in the same patients. Abbreviations: TTE = transthoracic echocardiogram, TCD = 
transcranial Doppler, TOE = transoesophageal echocardiogram, TP = true positive, FP = false positive, FN = false negative, 
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Comparison Between Grade A and Grade B Studies 
There were no differences observed for specificity for either technique, irrespective of whether 
TOE confirmation was used (Fig. 15). For TCD, there was a trend towards higher sensitivity 
when TOE was used for comparison: without TOE (0.83, 95% CI 0.78-0.87) compared with 
TOE (0.91, 95% CI 0.86-0.94). In comparison, TTE saw a decline in sensitivity: without TOE 
(0.87, 95% CI 0.83-0.91) compared with TOE (0.81, 95% CI 0.76-0.85) (Fig. 15). 
 
Discussion 
This meta-analysis has shown that TCD is superior to TTE for detecting right-to-left shunts in 
patients who have experienced stroke or migraine when TOE is used as a gold standard. The 
specificity remains high for both techniques, irrespective of whether TOE is used as a gold 
standard. This indicates that TCD should be considered the first imaging test of choice for 
patients where a paradoxical embolism through a PFO is suspected. However, when no gold 
standard was used the sensitivity of TCD was significantly lower, and closer to that of TTE. 
 
TCD is Superior to TTE for the ruling in of a Patent Foramen Ovale 
TTE with harmonic imaging and agitated saline contrast is frequently used to screen for PFO 
as part of routine clinical care.13 Despite its consistent use, studies involving TTE for PFO 
detection have been inconsistent in regards to the sensitivity of TTE when compared to the 
gold standard TOE.48,128 There are multiple reasons that can be attributed to this inconsistency, 
such as the inability to perform the Valsalva manoeuvre during TOE,79 or poor imaging quality 
using TTE.92 An alternative diagnostic method, TCD, challenges the sensitivity and specificity 
of TTE and TOE, is minimally invasive, and can be used by the bedside similarly to TTE.74 
However, TCD also comes with pitfalls such as the inability to decipher between an 
intracardiac shunt and an intrapulmonary shunt, which is often reflected in TCD’s specificity.93 
In the present meta-analysis and systematic review, studies comparing TTE and TCD against 
a gold standard reference technique were compared to studies that did not use a gold standard 
technique, the sensitivity of TTE dropped (0.87 - 0.81) (Fig. 15). Opposingly, the sensitivity 
of TCD increased (0.83 - 0.91) (Fig. 15). Prior to the addition of the gold standard, the 
sensitivities of TTE and TCD were relatively similar (TTE: 0.87, TCD: 0.83), and the 
confidence intervals overlapped (95% CI 0.83-0.91 for TTE, 0.78-0.87 for TCD) (Fig. 15). 
However, when studies involving TOE were included, the confidence intervals widened, 
bridging the gap of sensitivity between TTE and TCD (95% CI 0.76-0.85 for TTE, 0.86-0.94 
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for TCD). The improvement in sensitivity for TCD with TOE reflects a reduction in the number 
of false negatives, as sensitivity is the number of true positives divided by the sum of the true 
positives and false negatives. This was true in the present study, where there were 48 false 
negatives when TCD was used without TOE, and only 20 when TOE was used (Fig. 15). 
However, there were 7 false positives with TCD that were not present on TTE. 
 
In the A grade studies (those with TOE confirmation), the forest plot demonstrates an increase 
in sensitivity over time for TTE. This is reflective of the evolution of the technique throughout 
the 1990s into the late 2000s as imaging improved and harmonic imaging was introduced.129 
This increase in sensitivity does not seem to be as prominent in TCD, although the TCD device 
has also seen significant improvements in detection over time.71 The ROC curves are also both 
very strong, indicating that despite inconsistencies, both methods bring strong diagnostic 
capabilities for PFO detection. It has helped that over the years the target population for PFO 
screening has been clinically refined. Although it is still under debate, the association between 
CS and PFO is understood now more than it was in the 1990s which has helped decipher the 
target population for PFO screening. Therefore, the prevalence of PFO in patients undergoing 
a bubble study is higher now than in the 1990s. This is somewhat demonstrated in the present 
systematic review and meta-analysis, as the two papers with the highest prevalence of PFO 
detection (83% and 77%) were conducted in 201069 and 2011,125 and the four studies with the 
lowest prevalence of PFO detection (26%, 35%, 36%, 39%) were conducted in 1993,81,123 and 
1997,53 with the exception of Souteyrand et al.,122 which was conducted in 2006 (prevalence 
of 35%).  
 
Current Perspective in the Literature Comparing TTE and TCD 
There are several meta-analyses that have looked at the diagnostic ability of TTE and/or TCD 
against the gold standard TOE.78,79,93 While they are all recent, none of them are limited to 
studies that applied both techniques to the same cohort of patients. The generalised outlook 
seemed to present TTE as the less sensitive, but more specific technique across the three 







Table 10: Comparison of Meta-analyses that investigate TTE and/or TCD against TOE 
 TTE 
SENSITIVITY 
(%, 95% CI) 
TTE 
SPECIFICITY 
(%, 95% CI) 
TCD 
SENSITIVITY 




REN ET AL.,78 
2013 
88 (79-94) 97 (92-99)   
MOJADIDI 
ET AL.,79 2014 
  97 (94-98) 93 (86-97) 
KATSANOS 
ET AL.,93 2016 
45 (31-60) 100 (97-100) 96 (93-98) 92 (86-96) 
PRESENT 
STUDY 2020 
81 (76-85) 100 (98-100) 91 (86-94) 97 (94-99) 
Legend 10: Weighted sensitivity and specificity for the present study were taken from the results of the A grade studies (studies 
that compared TTE and TCD against TOE). Abbreviations: TTE = transthoracic echocardiography, TCD = transcranial 
Doppler, TOE = transoesophageal echocardiography, CI = confidence interval. Note: only the present study included the 
same patients in both TCD and TTE comparisons. 
 
Katsanos et al.,93 evaluated the sensitivity and specificity of both TTE and TCD against the 
reference standard TOE. However, the included studies did not require the application of TTE 
and TCD in the same patients, it merely includes all papers that compared TTE to TOE, or 
TCD to TOE in the same meta-analysis. Katsanos et al., also uncovered a very poor sensitivity 
for TTE (45%), which was attributed to poor imaging quality93 and acknowledged that imaging 
quality has improved over time for TTE. However, the two studies that gave the lowest level 
of sensitivity for TTE were conducted in 2003 and 2006, which is after the introduction of 
harmonic imaging.130 They eventually concluded that TTE was the best option for ruling in a 
PFO as it has a higher likelihood ratio compared to TCD and is therefore more likely to 
diagnose a PFO as a true positive, but for the general diagnostic yield, TCD outweighed TTE.93 
Ren et al., found TTE to have reasonable specificity (88%),78 especially when compared to 
Katsanos, or the present study. While 88% was the highest level of sensitivity out of the three 
meta-analyses that compared TTE to TOE, it is still far from perfect and Ren et al. put this 
down to age, initial disease, PFO size, and acoustic window.78 They argued that older age 
prevented patients from performing an adequate Valsalva manoeuvre, and increased the 
amount of age related fat, decreasing the sensitivity of TTE.78 Mojadidi et al., found TCD to 
be the most specific (97%) of the three studies that compared the technique.79 They found that 
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increasing microbubble threshold from 1 microbubble to 10 microbubbles increased the 
specificity (89 – 100%) without compromising sensitivity (98 – 97%) for positive PFO 
detection.79 They put this down to shunt type, with a cut-off used to decrease the number of FP 
results created by insignificant shunts (intrapulmonary shunts).79 However, this is controversial 
as small shunt size does not necessarily rule out a shunt through a smaller PFO.131    
 
TTE and TCD are relatively similar in some ways, such as they are both used by the bedside, 
are non-invasive, and run at a reasonably low cost.74,104The TCD device is easy to operate and 
interpret and is highly sensitive, as well as being portable for a diagnosis in the ward.132 TTE 
also has several diagnostic advantages as it is able to rule out other cardiac sources of emboli 
(such as an pulmonary arteriovenous fistula, left ventricular thrombus, left ventricular 
dysfunction, dilated atria, or valve disease), by imaging the heart directly.87 This is somewhat 
reflected in the results of this meta-analysis. For example, studies without TOE used as a 
reference standard showed a higher level of sensitivity using TTE compared to TCD (87% and 
83% respectively). This may be indicative of TTEs ability to recognise and diagnose the 
location of the shunt (i.e. which shunts are occurring through a PFO, rather than through an 
intrapulmonary shunt).78 On the other hand, if a timing technique such as the rule of 9 is not 
applied TCD classes any microbubble passing through the MCA as a general RLS, rather than 
a positive PFO.75 The rule of 9 is when a PFO is deemed to be present when at least nine 
microbubbles pass through to the left heart and appear in the MCA within 9 seconds of 
injection, and helps the clinician differentiate between shunt types using TCD.89 
 
Implications of the Results in Current Literature 
The accurate diagnosis of a PFO is important for young patients experiencing migraines, or 
who have had a cryptogenic stroke. If left undiagnosed, a PFO can allow the passage of venous 
emboli into the arterial system, which can cause a trail of cerebral destruction.13 The 
importance of an accurate diagnosis allows the consideration and planning of secondary 
prevention, whether that involves percutaneous closure of the PFO using an Amplatzer 





Limitations of the Diagnostic Techniques and Current Gold Standard 
It still remains unclear which method should be regarded as the ‘true’ gold standard. Although 
this study has referred to TOE as the gold standard, it may be an imperfect one.48 This is 
because sedation is often used during TOE which can lead to false negative results if the patient 
cannot perform an adequate Valsalva manoeuvre.17 A gold standard approach that requires the 
presence of a PFO in two of the three methods of detection has been suggested and indeed used 
in a study by González-Alujas et al., which may be a suitable approach. This ‘two out of three 
diagnosis’ would alleviate the uncertainty TOE holds as a gold standard and would improve 
the likelihood that the correct diagnosis is being made. For example, it may involve a two-step 
primary bedside method of PFO detection using both TCD and/or TTE, prior to the patient 
having a TOE. If both of the TTE and TCD are positive, the patient is diagnosed with PFO 
prior to the TOE, which can then be conducted with the primary intention of determining the 
PFO for suitability for repair. If only one is positive the TOE may be used for a confirmatory 
diagnosis as well as assessing the suitability for repair. However, TTE still holds an advantage 
as it can rule out other sources of emboli that may have contributed to the presenting condition. 
And thus, it may be argued that TTE should be the first method used, and if positive, direct 
referral to TOE, but if not positive further assessment by TCD may be beneficial (Fig. 18). For 
example, if the sensitivities of TCD and TTE calculated in the present study were applied to a 
hypothetical 100 person cohort with an 80% prevalence of PFO, TCD would detect 73/80 true 
positive patients, while TTE would detect 65/80 true positive patients. The use of TCD as an 
additional method of diagnosis would detect 7 more true positive cases that TTE otherwise 
would have missed, highlighting the benefit of adding this extra diagnostic step.  
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18. Proposed diagnostic pathway for PFO diagnosis 
 
Figure 18. Patients will be assessed following a cerebral event, factors such as age, co-morbidities, RoPE score, etc will help 
clinicians decide the next steps. Patients with a likely cryptogenic stroke will be referred for a routine TTE, and bubble study 
which would usually indicate the presence or absence of a PFO. The proposed pathway suggests that in clinical situations, a 
TCD will be undertaken either concurrently, or following the TTE + agitated saline. Abbriviations: PFO = patent foramen 
ovale, CVA = cardiovascular assessment, TTE = transthoracic echocardiography, TOE = transoesophageal 
echocardiography 
Bias within the A and B grade studies 
The QUADAS 14-item checklist indicated that, in the majority of the studies, there was limited 
bias. One study that indicated a high level of bias was Corrado et al.125 The paper itself provided 
limited information and so the author was approached and thus provided us with raw results 
which allowed for the inclusion of this study into the meta-analysis.125 Although it scored 
poorly for bias – this is a result of the nature of the way the paper was presented to us, and not 
on the methodological quality it possesses.  One source of bias may be patient selection. 
However, this meta-analysis was conducted with the aim to compare the diagnostic abilities of 
TTE and TCD for the presence of a PFO, not to evaluate the prevalence of PFO in the 
population. Therefore, in regard to patient selection, selection bias is not present if the study 
group only contains patients referred on to a clinician following a cerebral event or migraine. 
To ensure that this was consistent, if studies used a control group to represent the general 
population, this group was removed (if possible) and if not possible, the study was excluded. 
For example, the B grade study by Itoh et al., involved two control groups in the study to 
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represent a healthy cohort (n=11) and a stroke cohort with obvious aetiologies (n=11), which 
were soon removed during extraction. This study indicated which patients were positive with 
TTE/TCD so this could be done without skewing results.124 Often patients were only referred 
on to a second technique after a positive first technique.134 If this was the case the study was 
excluded. If these particular studies had been included, a PFO that may have been initially 
misdiagnosed as negative would never be challenged by a secondary technique. This would 
result in an overestimation of specificity for the initial reference technique.  
 
Study Limitations 
This study had several limitations. Some of these studies had a sub-par methodological quality, 
which is why some studies were classed as grade A, and some as grade B. Additionally, many 
studies had some degree of selection bias with the study design, which allowed some methods 
to screen more patients than others. The authors of some studies which may have been eligible 
for inclusion were approached for further investigation, but if they did not respond the study 
was excluded. Some papers may have been suitable in terms of comparing TTE and TCD but 
had to be excluded as the cohort was not in stroke or migraine patients. Additionally, 
publication bias was a limitation to this study, as only published work was able to be reviewed. 
The higher prevalence of PFO in this study may not translate over to the prevalence of PFO in 
the general population. However, as aforementioned, the studies included were conducted to 
investigate the diagnostic capabilities of TTE and TCD, not observe overall presence, so 
patients with suspected PFO would be put forward for assessment. With that in mind a higher 
prevalence of PFO can be somewhat expected as the mechanisms behind PFO are now more 
understood than ever, refining the patient population getting referred on for a bubble study. 
Furthermore, although the techniques were all described in detail for the majority of the studies, 
we were still unable to determine how similar the application of methods between studies was, 
meaning the standardisation of the techniques was a further limitation to the present study. 
 
Conclusion 
This systematic review and meta-analysis showed that TCD was the more sensitive method, 
but the less specific method compared to TTE when TOE was used as a gold standard reference 
technique. When there was no gold standard used, both techniques showed a lower level of 
sensitivity. To our knowledge, this is the first meta-analysis conducted to look at the use of 
both bedside techniques (TTE and TCD) in the same patients presenting with CS or migraine. 
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This if of importance as there is discussion within the literature regarding the current gold 
standard TOE, and how it may not be the optimal method in terms of sensitivity or specificity. 
By comparing the two bedside techniques in the same cohort the best comparison can be made. 
The study was conducted by three reviewers and was assessed for all forms of bias. As more 
evidence comparing TTE and TCD emerges in the literature, the evaluation of TTE and TCD 
can be further discussed and clearer conclusions can be made, which will only have a positive 









Chapter Four: Discussion 
 
Summary of Results 
This thesis has discussed the implications of the link between patent foramen ovale (PFO) and 
ischaemic stroke, investigated ways in which PFO can be diagnosed in case studies, and 
systematically reviewed current literature to find the optimal diagnostic method. In the case 
studies, all three of the patients were diagnosed with a PFO, two of which were deemed to be 
an incidental finding. Benefits and pitfalls were revealed for both transthoracic 
echocardiography (TTE) and transcranial Doppler (TCD) during the case studies, making the 
judgement of the optimal technique even harder. While TCD was able to diagnose one 
particularly at-risk case with a shower curtain sized shunt, it lacked the ability to optimise the 
middle cerebral artery (MCA) in a patient where there was an absence of temporal bone 
window. TTE was able to positively diagnose all three shunts as intracardiac shunts, and 
directly image the septum, as well as other areas of the heart. However, at times TTE struggled 
with imaging due to inflated lungs when a standardised method of the Valsalva manoeuvre was 
conducted. The meta-analysis found that TCD was the optimal test for the ruling in of a PFO, 
but only when transoesophageal echocardiography (TOE) was used as a gold standard. 
Otherwise, the optimal test was not obvious. A shift in sensitivities was seen for both 
techniques when TOE was included as a gold standard.  
 
The diagnostic abilities of TTE versus TCD is still under debate  
Discrepancies within the literature continue to fuel the ongoing debate regarding the optimal 
method for PFO detection for patients who have experienced cryptogenic stroke (CS). Despite 
these discrepancies, both TTE and TCD are considered strong diagnostic tools. Several recent 
large scale studies have used either TTE51,135 or TCD65,91,127 as reliable diagnostic methods to 
detect the presence of a right-to-left shunt (RLS) in patients presenting with CS or migraine. 
Various studies have compared the techniques side by side with and without comparison to a 
reference standard, and the common trends tend to be; higher sensitivity of TCD,34,122,127 and 
higher specificity of TTE.34,69,12269,122 Most of the time this was attributed to TCD’s inability 
to differentiate between shunt types, and TTE struggling with poorer image quality and smaller 




TTE has several distinct advantages over TCD in regards to imaging the heart directly. TCD 
has lower specificity compared to TTE, which may be due to extracardiac shunts causing false 
positive results.93 Additionally, because TCD does not image the heart (and therefore the 
contrast) directly, it will not be able to tell if a poorly timed Valsalva manoeuvre was performed 
– which may result in a RLS of blood, but without contrast. If this occurs, TCD will not be able 
to image any microbubbles, indicating the absence of a PFO leading to a false negative 
diagnosis.48 Furthermore, TTE, unlike TCD, is able to image larger shunts without a saline 
contrast or a Valsalva manoeuvre by using either 2D imaging alone to assess the interatrial 
septum, or using color Doppler to visualise the movement of oxygenated blood from the right 
atrium (RA) across the interatrial septum into the left atrium (LA).68 This approach to PFO 
detection is not very specific and the technique improves significantly when contrast and the 
Valsalva manoeuvre is used.68  
 
More generally, TTE is also able to broadly evaluate the functioning of the heart to assess for 
a range of conditions that may cause stroke or other dysfunction (Table. 11).136,137 This 
demonstrates the versatility of TTE as a technique when imaging heart. TCD also has several 
other uses in clinical practice, but not as many that evaluate conditions or measures directly 
attributed to the cause of stroke (Table 11).105,138–140 
Table 11: Diagnostic abilities of TTE and TCD for conditions other than PFO 
TTE TCD 
- Left atrial myxoma 
- Valvular vegetation 
- Left atrial appendage 
- Left ventricular thrombus 
- Left ventricular aneurysm 
- Dilated cardiomyopathy 
- Aortic stenosis 
- Mitral stenosis 
- Mitral valve prolapse 
- Mitral annular calcification 
- Ejection fraction 
- Wall motion abnormalities 
 
Conditions directly involved in stroke: 
- Intracranial steno-occlusive disease 
- Subarachnoid haemorrhage 
(vasospasm) 
- Extracranial disease 
- Atherosclerosis of cerebral blood 
vessels 
- Hyperaemia 
- Sickle cell disease 
May have some involvement in stroke:  
- Intercranial pressure 
- CO2 reactivity and autoregulation 
- Brain death 
Legend 11: Table describes other conditions that TTE and TCD can clinically evaluate other than PFO presence, highlighting 
the alternative uses of each technique for detecting cause of stroke or general abnormalities. Abbreviations: TTE = 
transthoracic echocardiography, TCD = transcranial Doppler, PFO = patent foramen ovale. 
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Several older studies have highlighted a lower sensitivity of TTE.81,82,124 Most attributed this 
to low image quality, and therefore the inability to diagnose smaller shunts or shunts during 
the Valsalva manoeuvre. However, with the introduction of harmonic imaging the image 
quality has improved and with it the sensitivity of the test.48 This was apparent in my meta-
analysis. If the pooled sensitivities for grade A studies were calculated separately for studies 
prior to 2000 and studies after 2000, studies prior gave a range of sensitivity from 47% to 
72%53,81,82 while studies after gave a range of sensitivity from 57% to 100%34,48,69,122. This 
shows an improvement in the application and ability of TTE, and puts forward the question: 
does the current ability of the technique need to be reassessed with studies that must include 
harmonic imaging? 
 
As well as the inability to image the heart directly, TCD has other pitfalls. If the timing of 
microbubbles appearing in the MCA is not measured, TCD is unable to determine if a shunt is 
intracardiac or intrapulmonary. Additionally, the lack of a sufficient temporal window may 
impair the ability for TCD to insonate the MCA. This was the case in case study 3. This is not 
an uncommon problem, and has been shown to affect 10-20% of stroke patients.91 Hu et al., 
found that woman were also more likely than men to have an insufficient temporal window, 
with twice as many older (>60 years) females having an insufficient window compared to men 
in the study.141  A study by Duan et al., demonstrated that 9% of people who were under 
investigation for PFO presence had an insufficient temporal bone window, and were 
subsequently excluded from the study.90 This is a major pitfall of TCD as a diagnostic 
technique. Alternatives to the temporal window such as the transorbital approach,90 
suboccipital approach,142 or submandibular approach114 are possible. They image separate 
cerebral arteries at different depths, and often require the power of the transducer to be reduced. 
The Italian SISIFO study successfully used the trans-occipital approach at a depth of 70-90mm 
as an alternative to participants without a suitable temporal bone window.23 However, similar 
to TTE, some patients do not have an adequate acoustic window for imaging, despite best 
efforts to optimise the image. Adequate training  and continued experience using TCD is 
required  to minimise technical errors and optimised utility of TCD. 
 
Impact of Shunt Size 
There is inconstancy within the literature regarding PFO size and stroke recurrence. While 
some studies say that larger shunt size is often correlated with a ‘high risk’ PFO (more likely 
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to cause recurrence),143 others have found no correlation between shunt size and stroke 
recurrence.144 The Risk of Paradoxical Embolism (RoPE) score is a newly developed score that 
helps the user determine the causal relation of the PFO to the CS.31 It uses risk factors such as 
age, smoking status, history of hypertension, stroke, or diabetes, as well as if a cortical infarct 
was present on imaging to rank the patient from 1 – 10.95 A high RoPE score indicates a high 
chance of the PFO being causal to the CS, and vice versa. However, a high RoPE score is 
matched with a lower risk of recurrence, indicating that since the patient is in reasonable health 
(and therefore ranked highly on the RoPE score) they are less likely to have a recurrent event, 
compared to those with a lower RoPE score.94 While the size of a PFO does not influence the 
RoPE score, several papers have made an association between smaller shunt size and stroke 
recurrence. In a very recent study, Turc et al., found that those with a smaller shunt were more 
likely to have recurrent events in CS patients compared to those with a larger shunt (1.3 vs 0.6 
incidence rate of recurrent stroke per 100 person years, respectively).143 Thaler et al., also found 
that smaller shunt size is associated with recurrent stroke.95 Although these findings are 
relatively novel, and somewhat unexpected, the true mechanism behind recurrent stroke and 
high RoPE score is yet to be uncovered.95 It may be possible, that once the mechanism is more 
understood, the size of the PFO and consequential shunt could be included in the RoPE score 
as it may indicate the contribution of PFO to the CS, as well as the likelihood of it causing 
recurrence. For example, Wessler et al., found that a large RLS diagnosed with TCD was 
correlated with high RoPE score, indicating that there is an alignment of some sort between 
the two.145 More generally, the lack of knowledge regarding the effect of shunt size on future 
recurrence stresses the importance of each diagnostic technique being able to accurately detect 
and grade a PFO, even if it may be small, and highlights an advantage of TCD and a pitfall of 
TTE, especially as a first choice of imaging modality. TCD, which has a much more sensitive 
5-point grading scale compared to TTE, may be more suited to assessing for RLS on the 
frontline. Its ability to detect a singular microbubble travelling through the MCA puts it at a 
distinct advantage compared to TTE for diagnosing smaller shunts in particular.  
 
The sensitivity of TTE also seems to be positively associated to PFO size.78 This is likely to be 
due to the image quality of TTE impairing its ability to detect smaller shunts.17 The sensitivity 
of TTE appears to increase with shunt size in some of the papers in the meta-analysis that used 
TOE confirmation.34,69,81 This may have contributed to the lower pooled sensitivity of the 
studies with a higher prevalence of smaller shunts than larger shunts. Zito et al., found that 
TTE was able to detect just over half the shunts found by TOE, however, of the shunts that 
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TTE did detect, 92% of them were classed as medium or large shunts.34 Additionally, Maffe et 
al., found that while TTE only managed to detect 63% of the medium sized shunts, the method 
was able to detect 96% of the large shunts.69 Di Tullio et al, found this increase in sensitivity 
to be true in both TTE and TCD, with the increase seen in patients with CS rather than stroke 
of determined cause.81 This indicates that the larger shunts were more easily detected compared 
to the smaller shunts that may have been an incidental finding in those with a stroke of 
recognised origin/cause.81 While sensitivity is still an ongoing issue for TTE, studies have 
investigated the use of a 5 microbubble cut off to help improve the specificity of TTE, and have 
shown promising results (increase of specificity from 57% to 89%), especially when used with 
abdominal compression.51    
 
Is the Current Gold Standard Adequate? 
The use of TOE as a gold standard method is widely applied in the literature.88 In the present 
thesis, the meta-analysis showed a shift of sensitivities in studies with TOE as the gold 
standard, and studies without a gold standard (Fig. 15). While the sensitivity of TCD improved, 
the sensitivity of TTE declined. To our knowledge, this meta-analysis is novel in the way it 
compared pooled studies that included both TCD and TTE with and without a gold standard. 
Reasons that may have attributed to this difference may be: TCD being the most sensitive 
method, TTE providing false negative results due poor imaging quality, or TOE providing false 
negative results and therefore misdiagnosing what may have been correctly diagnosed patients.  
 
In the case series, none of the patients were referred on for a TOE, so TTE and TCD could not 
be compared against a gold standard. Cases 1 and 2 had a positive result with both TTE and 
TCD indicating a PFO was present; case 3 was unable to have the TCD due to an insufficient 
temporal window, but was deemed to have a PFO after a positive TTE. The current use of TOE 
as a gold standard is controversial85 as it has a higher than average reporting of false negative 
results due to patients being unable to perform an adequate Valsalva while under sedation.88 
The case studies have demonstrated the ability of a mixed two-method approach of PFO 
detection that appears to be highly accurate. Several other studies have proposed alternative 
gold standard references or pathways of diagnosis. Caputi et al., suggests TCD and TTE should 
be the first methods of choice for PFO diagnosis,88 which Komar et al., somewhat agrees with, 
suggesting that the patient should only go on for a TOE if assessment for closure is needed.74 
Stafford et al., proposes that TCD should be the first method of screening. If negative the 
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patient should have a TTE, but if positive the patient should go on to a TOE for assessment.68 
González-Alujas et al., took a different approach, and used the presence of a PFO to be 
definitive if there was concordance between any two techniques in their diagnosis.48 While the 
present study is too small to be conclusive, and has not been able to assess the ability of TOE, 
the resulting pitfalls and advantages of TCD and TTE are similar to those in large scale studies. 
It is obvious that more information is needed to propose and establish an alternative gold 
standard that challenges TOE – whether this may be a single technique or a mix of several.  
 
Consistency of the Valsalva Manoeuvre 
The Valsalva manoeuvre increases the sensitivity of TTE, TCD and TOE by shunting 
microbubbles through a PFO, were there to be one.52 However, studies tend to be inconsistent 
between their application of the manoeuvre – with some studies teaching patients the prompt 
prior to the assessment,48 some using a calibrated device,146 some using a coughing technique,53 
and some using abdominal compression.51 All of these techniques work – but some are better 
than others. In the present thesis, 3 different techniques were applied to the case studies, all of 
which produced a different result. When a calibrated device was used in case 1, the sonographer 
could not image due to inflated lungs; in case 2 abdominal compression was applied which 
resulted in a very large RLS; and in case 3 the patient was asked to perform the Valsalva 
manoeuvre on their own accord (no prior training).  
 
The use of either a trained Valsalva manoeuvre, or a backup technique (such as abdominal 
compression) after an unsuccessful Valsalva manoeuvre appeared to pay off in regards to the 
sensitivity of TTE in both A and B grade studies in the present meta-analysis. González et al.,48 
and Maffè et al.,69 used either a secondary technique after a failed Valsalva manoeuvre, or 
trained their patients prior to the assessment, and had the highest levels of sensitivity for TTE 
in the A grade studies (100% and 89% respectively). Contrastingly, Di Tullio et al.,81 and 
Nemec et al.,82 both did no prior training and had no backup technique and showed the lowest 
levels of sensitivity for TTE (47% and 50%). A similar trend can be seen amongst the B grade 
studies – patients trained to perform the Valsalva manoeuvre prior to assessment had a 
sensitivity of 94% for TTE (Corrado et al.125) whereas patients with no prior training and 




The use of abdominal compression to prompt a more successful Valsalva manoeuvre is an up 
and coming technique that has shown promising results when using TTE, TCD, and 
TOE.51,54,147 It is particularly useful in sedated patients during a TOE,147 when a normal 
Valsalva manoeuvre is unsuccessful,148 or in patients that have abdominal obesity.54 In case 2, 
the patient was classed as obese, and showed small shunting during a normal Valsalva 
manoeuvre on both TTE and TCD. However, when abdominal compression was applied, a 
large shunt was seen on both methods, indicating the severity of the shunt and therefore 
suggesting the need for treatment which was later carried out. This emphasises the importance 
of a proper Valsalva manoeuvre so the shunt can be graded with the highest level of accuracy 
and an educated decision can be made regarding treatment versus no treatment. More generally, 
it emphasises the importance of creating the largest shunt through a PFO in time with the saline 
injection, in order to optimise imaging.  
 
Clinical Application 
Stroke is a leading cause of death and disability worldwide, and cryptogenic strokes are 
believed to account for up to 30% of all ischemic strokes.149 A CS is as a stroke that has an 
undetermined pathogenesis and its cause cannot be attributed to the usual sources of embolism 
that can cause an ischemic stroke.150 The presence of a PFO appears to be associated with CS, 
and the diagnosis of a PFO may provide an answer to those patients with CS as to how 
embolism occurred.22 When a patient is diagnosed with a PFO, clinicians must determine the 
contribution of the PFO to the presenting condition (was it an incidental finding or 
pathological), the risk of the PFO causing recurrent events, and the decision going forward 
(leave the PFO, administer oral drugs to hinder recurrence, or close the PFO). Factors that 
weigh in on these conclusions often involve shunt size, current medication, age of patient, 
existing health conditions (such as hypertension, obesity, previous history of ischemia), or the 
presence of ischemia on magnetic resonance imaging (MRI). There is a higher chance of CS 
patients presenting with a PFO than in the general population.47,134,144 The mechanism behind 
this relationship is thought to be due to the PFO providing a route for venous, unfiltered blood 
to cross the interatrial septum into the arterial system where it can cause ischemia if an embolic 
source gets lodged in a cerebral artery.13 Although a relationship exists between the two, the 
presence of a PFO is not necessarily causal for CS.117 This relationship is still under 
investigation, so it is imperative that the techniques used to assess for a PFO provide the utmost 
level of clarity so the correct assessment and decision can be made going forward. As studies 
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produce novel findings about each diagnostic technique, and methods that help enhance them, 
the precision of the diagnoses improves. This present thesis has explored two diagnostic 
techniques (TTE and TCD), and highlights issues and benefits of each in real life case studies.  
 
The contribution of PFO to stroke and other conditions 
A patent foramen ovale does not only have a relationship with cryptogenic stroke, but has been 
linked to other conditions such as migraine151 and decompression sickness.9 The pathology of 
migraine is still under debate, but is thought to be due to a phenomenon called ‘cortical 
spreading depression’ which is characterised by a self-propagating wave of cortical excitation 
closely followed by temporary depression of neuronal activity leading to headache-like 
symptoms.131 PFO size appears to have a correlation with migraine. Schwerzmann et al., found 
a PFO in 47% of migraine patients compared to 14% of healthy controls, and found that larger 
shunt size was correlated with presenting migraine.131 Monte et al. found that the PFO diameter 
was smaller in patients with migraine compared to those with CS.152 Additionally, it has been 
said that TTE is less sensitive when it comes to smaller PFOs, and may therefore be less 
accurate in detecting patients with migraine.78 The grade A study by Zito et al., which 
comprised of 50% migraine patients, matches this finding as TCD demonstrated a high level 
of sensitivity (96%) compared to TTE (57%) when compared against the gold standard TOE.34 
While the general consensus seems to indicate some form of correlation between PFO and 
migraine,12,24,98 a large scale trial by Mattle et al., found that the closure of PFO did not decrease 
the number of monthly migraines in a cohort of patients undergoing closure due to migraine.36  
The association between migraine and PFO warrants further exploration and while the present 
thesis does not explore migraine directly, it does add to the conversation regarding its 
association with PFO and the ways it can be detected. 
  
Peripheral Emboli 
While the majority of the focus regarding paradoxical embolism lies with neurological 
disorder, the effects of emboli travelling downstream to the periphery has been somewhat 
ignored. Case 2 and case 3 in the present thesis both showed emboli travelling downstream 
using TTE (Case 3 – Fig. 12). While the PFO in both cases was classed as severe using TTE, 
case 3 showed notably less microbubbles in the left heart compared to case 2. The fact that 
peripherally travelling emboli were still seen in case 3 indicates that the percentage of bubbles 
travelling downstream may be higher than anticipated. A case study by Daly et al., investigated 
 
 71 
a patient with upper limb ischemia that had a large PFO discovered by TCD, but not TTE.153 
While TCD cannot visualise emboli travelling down the aortic arch, it can be speculated that if 
a shower is present, emboli will also be travelling downstream. Emboli that travel peripherally 
can cause complications if the blood flow to an artery providing blood to an organ (such as the 
kidney) is restricted.19,154 While the percentage of peripherally travelling emboli is still being 
discussed, Dao et al., found emboli travelling peripherally in 2.9% of patients undergoing 
assessment for PFO.19 Further study needs to be conducted to estimate the percentage of 
peripherally travelling emboli, in order to make stronger associations with peripheral events. 
A greater understanding between PFO and peripheral embolism may also promote the use of 
TCD as a diagnostic tool when assessing for the cause of peripheral embolism.  
 
Treatment and age 
Ischemic stroke accounts for around 87% of all stroke types, the majority of which occur in 
persons over the age of 65.8 However, in those under 65 years of age, up to 43% of ischemic 
strokes are classed as cryptogenic.50 As aforementioned, PFO size increases with age.13 Age 
plays a role in PFO diagnosis in terms of its causal effect, future risk assessment and what 
decision is made regarding treatment.13,25,31,68 Due to the accumulation of other comorbidities 
that tend to come with older age, the mechanisms behind stroke at an older age do not translate 
well to younger individuals.155 Younger patients (<55 years) that present with a PFO tend to 
be more at risk of recurrence RLS though a PFO compared to those who are older.13 Although 
the risk of general stroke recurrence is still higher in older patients due to other existing factors.  
Age is an important factor that needs to be taken into consideration when deciding on treatment 
for PFO. 
 
If the PFO is thought to be of concern for recurrence events, the decision to treat it using 
medical or interventional methods can be made. Medical treatment usually involves the 
administration of oral anticoagulants or antiplatelet agents, whereas interventional treatment 
usually involves the closure of the PFO using a device.10 Devices used for the percutaneous 
closure of a PFO have evolved through the years,156 and the Amplatzer septal occluder is now 
a common method of treatment for PFO. This method involves the physical closure of the PFO 
using an umbrella-like device put into place by a transeptal sheath via the femoral vein.157 One 
particular study by Cifarelli et al., observed the recurrence rates of patients having undergone 
PFO closure after 3 years.158 Patients under the age of 55 years showed a 1% recurrence rate 
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for an ischemic event, while those over the age of 55 years had a much higher recurrence rate 
of 16%.158 Although both of these recurrence rates are lower than the rate without treatment 
(20.4%),5 the older population is at a significant disadvantage. Older patients not only have a 
higher chance of device dislodgement,18 but are also more likely to have secondary health 
conditions and may already be on anticoagulants, hindering their ability to be administered 
more due to abnormal bleeding.159 While there have been several studies investigating the 
recurrent rates of a cerebral event in treated PFO patients following a small number of years,160–
162 few studies have looked at the recurrent rates over many years. Mono et al., looks at the 
long-term recurrent rates of the use of anticoagulants versus PFO closure and has given 
interesting results.117 In the anticoagulant group (mean age 51 ± 13 years, n=158) there was a 
20.3% recurrent rate, and 10.1% death rate after 8.1 years of follow up (± 4.7 years).117 On the 
other hand, the medical closure group (mean age 50 ± 12 years n=150) had a recurrent rate of 
10.7% and death rate of 4.7% over 9.2 years follow up (±  3 years).117 This demonstrates that 
the effectiveness of  transcatheter closure as a treatment option in the long run, compared to 
anticoagulants which appeared to have no long term benefit. Again, this cohort was under the 
age of 55 years, which indicates that this may be the best option for a younger patient (<55), 
rather than an older patient (>55). While this meta-analysis is not directly investigating 
treatment options for a PFO, the overarching importance of an accurate diagnosis in the first 
place is clear.  
 
Do Neurologists and Cardiologists diagnose a Patent Foramen Ovale differently? 
Cardiologists and neurologists tend to have different objectives when it comes to diagnosing a 
CS patient. Cardiologists are not only interested in the presence of a RLS, but the type of shunt, 
size of shunt, and how suitable the shunt is for closure, if needed. Neurologists may be more 
interested in the stroke and the determination of its cause. As a result, different specialists tend 
to assess the condition in different ways. For example, typically TCD is the first test used by 
neurologists and TTE by cardiologists, and their expertise is reflected in higher use of each test 
retrospectively. In the present meta-analysis, a study conducted predominantly by cardiologists 
had the lowest level of specificity for TCD (92%).69 Although the TCD procedure itself was 
conducted separately by a neurologist, there was no mention of the timing of microbubble 
appearance in the MCA. In fact they mention using a 25 second window of recording following 
the Valsalva manoeuvre. This would allow for intrapulmonary shunts to be included and 
confused with PFOs. Indeed, they conclude that TCD “does not allow a cardiac control of 
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shunts, loading more with false positives69”. This is likely to be what lead to the lower 
specificity of TCD through a higher rate of false positives.  
 
In 2013 Pristipino et al., conducted a large scale working group study to help create a shared 
management scheme for CS patients with a PFO.163 The study gave clarity around the 
diagnostic workout, described different scenarios that would indicate probable pathogenesis, 
outlined the different characteristics that a PFO could have and what they implied, and 
recommended medical and interventional therapies based on recurrence.163 However this was 
established the same year as the RoPE score by Kent et al., which essentially pooled the 
collective evidence presented by Pristipino, and made a tool which could indicate the causal 
effect of the PFO in terms of the CS and the likelihood of recurrence.31 The success of each 
paper and its suggestions can be reflected in the number of citations for each paper, with Kent 
et al., being cited six times more than Pristipino et al.  
 
Strengths and Limitation of this Thesis 
This study showed several strengths in the fact that the sample size, although small, 
demonstrated a variety of presenting issues with either technique. This enabled each technique 
to be properly criticized and added to the ongoing conversation around optimal method of 
detection. Additionally, the conduction of the meta-analysis was a huge strength as it was 
novel, and was able to provide some additional strength to my thesis when patient numbers 
were diminished. This study had several, large limitations. Firstly, the process around sourcing 
ethical approval took almost 4 months. Originally it was thought that approval through OUHEC 
was needed, but we later found that we needed to escalate the ethical application to HDEC. 
The decision to apply for an amendment to contact previous eligible patients was made (which 
was accepted). However, at this particular moment COVID-19 arrived in New Zealand, and 
the hospital was shut down. At this stage I had only recruited the 3 participants presented in 
this thesis. Lock down ended mid-way through May, bearing in mind my thesis was due in 
June. There was no further opportunity to recruit patients, and the lack of patients (anticipated 
to be a 40-60 person study) has had a severe impact on the statistical significance this thesis 
holds. Additionally, the reliability analysis was cut short by COVID-19 as I was unable to 
access the hospital and the TCD machine, so unfortunately only 2/5 participants were able to 
have all three reliability tests conducted, hindering the results. One particular limitation of this 
study was my inability to observe cerebral blood flow using TCD through an alternative 
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window. At the time of screening case 3, I had only ever practiced insonating the MCA, though 
the temporal window, and did not want to try a separate window for the first time on a patient. 
In hindsight, I should have practiced several other alternatives to the temporal window in case 
of its absence.  
 
Future Direction 
A lot of work is needed in this area to gain more clarity around the optimal method for PFO 
diagnosis. It is obvious that TCD is a promising diagnostic tool for a bedside diagnosis, but 
more information regarding its strengths and limitations is needed. This study investigated 
many aspects which could improve the diagnostic certainty of TTE and TCD, as well as TOE 
indirectly. More research into avenues such as the use of abdominal compression to provoke a 
RLS, the imaging of the aortic arch, and the injection of agitated saline into the femoral vein 
would be advantageous. To truly get a representation of the effects of these techniques a large 
scale study is needed that involves the use of TCD, TTE, and TOE. Whether or not TOE should 
be used as a gold standard is controversial, but it certainly brings more to a diagnosis than if it 
were absent. The application of the newly established RoPE score would be beneficial, as well 
as a follow up to indicate its accuracy of indicating the likelihood of recurrence. Treatment 
follow up in all of these patients, alongside a non-treatment group would help shed light on 
what types of treatment were better for what age, and how the RoPE score indicates this. More 
insight is needed regarding PFO size, as well as the effect of newly introduced imaging 
modalities in papers of different decades. Overall, a firm stance is known about PFO diagnosis, 
but there is certainly more to be known, which would be hugely beneficial to those diagnosed 
with PFO.   
 
Conclusion 
The present thesis has explored the potential techniques for PFO diagnosis in patients with 
ischemic stroke, cryptogenic stroke, or migraine. More clarity is needed as to which technique 
is optimal to detect a PFO, to determine its causal effect with CS, and to identify the longer 
term prognostic impact for the patient. We compared the two bedside techniques TTE and TCD 
in patients in the Southern District Health Board that presented with stroke, or stroke like 
neurological symptoms. Both techniques demonstrated good diagnostic ability, but neither was 
ideal. TTE was able to grade all three shunts, and indicate the most at risk shunt. However, it 
was less able when a calibrated device inflated one patient’s lungs. TCD gave great diagnostic 
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accuracy for 2/3 patients but was not able to produce a diagnosis on the third due to an 
insufficient temporal bone window. Two of the participants had the PFO classed as an 
incidental finding, which was attributed to no stroke like infarcts on later imaging, and a high 
chance of neurological symptoms being due to a mechanism unrelated to PFO. We also 
investigated the use of the two techniques in the current literature and found interesting results 
in terms of sensitivity when a gold standard reference was introduced. The current status of 
TTE and TCD in the literature aligns with the findings of the case study in regards to some of 
the pitfalls and advantages of each technique. The meta-analysis also found that several 
measures such as a consistent Valsalva manoeuvre, the year the study was conducted, or type 
of clinician performing the technique influenced the resulting diagnostic ability of the 
consequential tests. Overall, this thesis explored the use and current status of TTE and TCD as 
diagnostic methods for PFO detection. The treatment of a PFO can be lifesaving, so the 
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1.1. Study Title 
 





A patent foramen ovale (PFO), is a small hole in the heart that allows blood to pass 
from the right to left atrium. Young patients (<65 years) that have had a cryptogenic stroke are 
routinely screened using echocardiography for the absence/presence of a PFO. The gold 
standard for PFO detection is a transoesophageal echocardiogram (TOE), however it is an 
invasive procedure. A transthoracic echocardiogram (TTE), is less invasive and therefore 
performed initially. Transcranial Doppler (TCD) is an alternative method of detection, which 
is minimally invasive and may improve on the sensitivity of the TTE. Typically, TTE and TOE 
are performed within cardiology departments where these patients are referred, but TCD is not. 
This study will investigate and compare these three detection methods on a population of 
young, cryptogenic stroke patients.  
 
1.3. Lay Abstract 
 
A PFO is a type of hole in the heart that can be treated with a relatively low risk 
procedure. Under certain conditions, a PFO opens and allows blood clots to cross through the 
hole, which can cause a stroke. A stroke that does not have an identifiable cause is called a 
cryptogenic stroke, and patients that have a stroke of this nature are referred to the cardiology 
team to assess if the heart was involved in the origin of the clot. This can be completed with 
direct imaging the heart, or indirectly by imaging a blood vessel of the brain with ultrasound. 
This study will investigate the best way to identify the presence of a PFO in patients with a 
cryptogenic stroke by comparing these techniques.  
 
1.4. Scientific Abstract 
 
Patients with a cryptogenic stroke have an unidentified cause of emboli. These patients 
are often referred for an echocardiogram as a common cause of cryptogenic stroke is a PFO. A 
PFO can cause right-to-left cardiac shunting, allowing venous blood to traverse the interatrial 
septum, entering the arterial blood stream. The venous blood has microplaques and 
microemboli present that are typically filtered out by the lungs but, in the presence of a PFO, 
these can travel to the brain or other sensitive areas of the body without filtration. When this 
happens, these microemboli, or indeed larger emboli, may cause a stroke or systemic embolus. 
Echocardiography methods such as a TTE, TOE, or TCD paired with agitated saline, with and 
without provocation with the Valsalva manoeuvre, can be used to detect if the patient has a 
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PFO. Although TOE is arguably the gold standard for PFO diagnosis, it is invasive and often 
requires sedation which may impair the patient’s ability to perform the Valsalva manoeuvre. 
TTE is the first cardiac imaging investigation performed in the management of stroke, as it is 
non-invasive, can be performed at the bedside, and provides additional information beyond 
detection of PFO, such as identification of other features that are high risk for embolism, e.g. 
mural thrombus. Those who screen positive for a PFO may have a TOE to confirm findings, 
accurately identify the size, and help plan management. In some patients in whom a PFO is 
still considered likely, but it isn’t clearly identified with TTE, a TOE may be performed even 
if the TTE is negative. Literature regarding the sensitivity and specificity of TTE and TCD is 
contradictory, and there are limited studies directly comparing these methods in a sample 
population. This study will compare the diagnostic utility of TTE and TCD for PFO diagnosis 




This project aims to optimise the initial process of PFO identification in patients with 
a cryptogenic stroke. Specifically, the clinical sensitivity and specificity of the TTE will be 
compared to TCD in PFO diagnosis and in those who are positive to either method with the 
gold standard TOE. It will also evaluate different areas where agitated saline can be imaged 
(interatrial septum, aortic arch, and middle cerebral artery). This project will provide important 
information about the optimal approach to PFO detection and assessment of future embolic 
risk by adding to the evidence regarding PFO diagnosis.  
 
 
Figure 1: The primary objective from this study is to optimise PFO detection. Because of 
controversy in literature regarding the optimal detection method (TTE vs TCD), the study will 
use and compare both methods on all patients. If a PFO appears to be present, TOE will be 
used as the gold standard to reassess the PFO, as well as the sensitivity and specificity of both 




Student investigator:  
 
Hanna Van der Giessen (BSc (Hons)), Department of Medicine, Dunedin School of 




Primary investigators:  
Professor Gillian Whalley, (PhD, BAppSci, MHSc (Hons), DMU) Department of 
Medicine, Dunedin School of Medicine, University of Otago; 
gillian.whalley@otago.ac.nz 
 
Dr Sean Coffey, (MB, BS, FRACP, PhD), Department of Medicine, Dunedin School 
of Medicine, University of Otago; email: sean.coffey@otago.ac.nz 
  
Dr Luke Wilson (PhD), Department of Medicine, Dunedin School of Medicine, 
University of Otago; email: luke.wilson@otago.ac.nz 
 





As part of their regular clinical management patients with a cryptogenic stroke or 
systemic embolus are referred to the Dunedin Hospital cardiology team for the evaluation of a 
cardiac source of embolus, which includes a bubble study with agitated saline for PFO 
screening. These patients will be invited to participate in this research study. If the patient 
consents to this research study, in addition to the normal echocardiographic assessment the 
patient will also have their anterior and middle cerebral circulation assessed with TCD during 
the bubble study for PFO screening. The study cohort is expected to be a minimum of 40-60 








2.1. Background Information 
 
During foetal development, the foetus is provided with oxygen rich blood by the 
mother164. The oxygenated blood bypasses the developing lungs through a small hole called 
the foramen ovale, located in the septum between the right atrium (RA) and left atrium (LA) 
which normally closes soon after birth, allowing the blood to assume normal circulation 
through the lungs165. A patent foramen ovale (PFO) is a remnant of the foetal circulation where 
the foramen ovale does not close completely following birth, affecting ~25% of the 
population46. Even in healthy individuals, the venous circulatory system contains micro-
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plaques and small thrombi which are normally cleared by the lungs20. But in the presence of 
an inter-cavity connection (such as a PFO), a cardiac shunt where blood moves from the right 
to left atrial can lead to micro-plaques entering the arterial circulation with the potential to lead 
to an embolic stroke if they reach the brain19. Studies vary in regard to the percentage of strokes 
caused by an emboli reaching the brain via a PFO, but figures tend to indicate that the 
percentage lies between 2 – 11% of stroke patients46,166. Studies also show that cryptogenic 
stroke patients are significantly more likely to have a PFO compared to previously diagnosed 
stroke patients81.  
Patients having experienced a cryptogenic stroke are typically referred for further 
investigation. There are three common ways to detect a PFO. A transthoracic echocardiogram 
(TTE) paired with agitated saline uses ultrasound to observe microbubbles in the LA or left 
ventricle (LV), or directly traversing through the septum itself, indirectly indicating the 
presence of a PFO4. A transoesophageal echocardiogram (TOE) uses the same technique, but 
uses an ultrasound probe in the oesophagus, which provides higher resolution imaging of the 
septum (including direct visualisation of the PFO) and evaluation of the suitability for repair81. 
Transcranial Doppler (TCD) also uses agitated saline, but examines arteries closer to the brain 
such as the middle cerebral artery (MCA) which is supplied blood from the aorta, providing an 
indirect method of PFO detection79. During a TCD both visual and audio outputs are provided 
and a Spencer Shunt grade (1 – 5) is used to rank the size of the PFO. In echocardiography, the 
number of bubbles traversing the septum are noted, but the defect is not graded per se. 
Currently, when patients are being observed using any of these methods, they are asked to 
perform the Valsalva manoeuvre. This involves the patient forcing exhalation which causes a 
change in intrathoracic pressure; this action is used to elevate the pressure in the right atrium 
relative to the left atrium and therefore force the PFO to open and allow blood and agitated 
saline to pass through the PFO if one is present78.  
 
In New Zealand, current clinical approaches typically involve patient referral to an 
echocardiography laboratory where TTE and TOE can be performed, and TCD is rarely part 
of that diagnostic pathway. TCD has been promoted as having better sensitivity and specificity 
than TTE but is not commonly used in clinical practice46,74. It is common for TOE to be used 
when there is a high clinical suspicion of a PFO. 
Although many studies have focused on the role of a PFO in cerebral embolic events, 
it should be acknowledged that emboli that cross a PFO can also cause other systemic embolic 
events (such as in the kidneys and GI tract)19. Importantly, TCD will only indirectly provide a 
risk assessment for such emboli (as the emboli do not travel to the brain), but current 
echocardiography methods may detect the potential for non-cerebral embolic events. The 
addition of the aortic arch imaging will allow us to assess the risk of non-cerebral emboli as 
the direction of travel of the bubbles (into the neck vessels, or into the descending aorta) will 
be visualised directly. 
The detection of a PFO is important because closing the defect, using the minimally 






Figure 2: Proposed future clinical pathway, depending on the results of this study. Patients with 
a cryptogenic stroke will be referred for a routine TTE, and bubble study which would usually 
indicate the presence or absence of a PFO. The proposed pathway suggests that in clinical 
situations, a TCD will be undertaken either cocurrently, or following the TTE + agitated saline. 
Due to literature questioning the specificity and sensitivity of TTE compared with TCD, the 




It is estimated that approximately 20-25% of the New Zealand population are currently 
living with a PFO. At the moment, the primary method of PFO detection is TTE. While TTE 
has reasonable diagnostic accuracy, some studies have shown that the TCD method may 
provide even more diagnostic certainty46,53,74,93. There have been studies comparing the two 
methods, but not many comparing the two in the same patients, with the third method as a basis 
for specificity (TOE). By using the same two techniques on each patient, a consensus regarding 
the specificity and sensitivity of each technique will be more attainable, and the use of TOE in 
the stages closer to potential PFO closure will give an indication if either of the methods is 
providing the user with false or misleading diagnostic information.  
 
PFO detection has focused on two aspects: visualisation of non-transpulmonary 
microbubbles traversing from the right to the left side of the heart (using TTE or TOE), and 
detection of bubbles reaching the brain (TCD). These approaches ignore the fact that some 
bubbles, and therefore emboli, may actually travel to the descending aorta and lead to 
peripheral embolic events. To our knowledge, no research has evaluated the presence of 
agitated saline within the aortic arch, where bubbles would then travel into other parts of the 
body. This is of importance because hypothetically, although most of the shunted venous blood 
would travel to the brain, some blood will reach other parts of the body and cause complications 
(such as in the kidney). A more in depth understanding regarding the number of bubbles that 
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may be travelling in this direction will add to the literature about how a PFO can affect 
alternative parts of the body. It may also provide insight into the origin of other embolic events 
that affect the periphery, and perhaps indicate that aortic arch screening for a PFO may be a 
viable diagnostic option. 
 
This project also carries significance to both scientific literature and clinical practice. 
Firstly, the study will add to the evidence regarding PFO diagnosis, which may simplify and 
improve diagnostic procedures in the future. Secondly, improved detection of cryptogenic 
stroke patients may lead to improved management of such patients. Additionally, it may 
highlight another area where PFO detection could be useful. 
 




A minor potential risk is discomfort – some people find the pressure of the ultrasound 
transducer troublesome, but is usually minor. There is a small amount of transient pain 
associated with the intravenous cannula used with the agitated saline injection and participants 
will also have to give up their time.  Every effort will be made to minimize any discomfort and 
be as efficient as possible. 
2.3.2. Benefits 
 
The primary benefit from this study is that it will increase our understanding of how to 
manage patients with cryptogenic strokes. This study will add to the literature regarding the 
optimization of PFO detection methods. Some direct patient benefit may occur to participants 
in the study as some may have a more accurate diagnosis of PFO by the introduction of TCD. 
This will influence the decision whether or not they get the PFO closed, which may in turn 
prevent a secondary stroke or transient ischemic attack (TIA) in the future. By creating and 
finding more clarity, perhaps the detection of PFOs in the future will be done with more ease 






• To provide further insight into the best method for primary PFO detection in 
cryptogenic stroke patients by comparing TTE and TCD sensitivity and specificity, and 
in those who are positive with TOE as the gold standard of diagnosis. This will provide 
patients with a more specific, and sensitive diagnostic procedure and help practitioners 





• Additionally, this study will also image the course of saline bubbles through the aortic 
arch, which will give insight into the additional complications a PFO could cause in 
other organs in the body. It also may prove to be a superior method of PFO visualisation 
and/or detection too.   
 
4. STUDY DESIGN 
 
This is a prospective study that will involve participants referred to the Echo team for 
a bubble study to assess potential intracardiac shunt. The patients will be consented before 
they come to the echo lab. Most patients will have the TTE and TCD in the same sitting if 
a PFO is suspected. However, some patients (not included in Figure 3) will just have a 
routine TTE first, and then if a suspicion subsequently arises regarding a PFO, the patients 
will be referred back to this particular study and a TTE + TCD bubble study will be 
conducted. Patients that have the bubble study initially (as outlined in Figure 3) will ideally 
have the TTE and TCD on the same day, and they will be conducted at about the same time 
of day (the TCD will be after the TTE). Recorded results from both the TTE and the TCD 
will be recorded and saved for analysis at a later date. 
 







5.1. Inclusion Criteria 
 
a) Patients that have been referred to the echocardiography service for a routine TTE after 
a cryptogenic stroke or systemic embolus. 
b) Over the age of 18 
c) Willing and able to provide informed consent. 
d) Willing and able to comply with the study procedures. 
 
5.2. Exclusion Criteria 
 
a) Have another identified potential cause of cardiac emboli other than PFO in their 
routine TTE (e.g. left ventricular thrombus, myxoma, vegetation on valve). 
b) Patients who are unable to perform the Valsalva manoeuvre. 
c) Pregnancy. 
 
5.3. Recruitment and Enrolment Process 
 
Patients will be approached for the recruitment into this study when they are initially 
referred to the echo team for a TTE following a cryptogenic stroke or systemic embolism. This 
may include inpatients in the wards. Young stroke patients will usually have a bubble study 
during the same appointment as a structural TTE, so during recruitment, it will be made clear 
to the patients that the additional TCD will ideally be done on the same day as the TTE, to 
avoid patients having to return to the hospital. Most patients will have their TTE during their 
hospital admission. 
There will be no monetary compensation for this study, as it is a small addition to their 
usual clinical testing.   
Once patients have been asked if they would like to participate in this study, they will 
be given an appropriate period of time where they can then consider the offer, so they feel no 




The clinically indicated TTE and the research TCD bubble study will ideally be 
conducted on the same day, but, if the participant wishes, can be performed separately. Further 








6.1. Echocardiogram procedures 
 
• Echocardiography will be performed by a sonographer using standard 
echocardiographic machines (Vivid S6, E9 or E95, GE Ultrasound or SC2000Prime, 
Siemens Ultrasound). Images will be recorded according to the recommendations of 
the American Society of Echocardiography. Recorded images will be transferred for 
analysis using the TomTec Image-Arena (TomTec, Unterschleissheim, Germany). 
Views for left ventricular and left atrial assessment will include the apical 4-chamber, 
apical 2-chamber, apical long axis and short-axis views. Images of the right ventricle 
and right atrium will be recorded in the apical 4-chamber view. 
• Saline will be injected into the arm using a three-way tap, and two syringes of saline. 
In the three way tap the saline will be mixed with a little bit of drawn up blood to agitate 
the saline for optimal imaging. The volume of saline injected, as well as blood drawn 
up into the syringe for the saline agitation will be kept constant over all participants. 
• Following the injection of the agitated saline, the heart will be continuously imaged and 
subsequently recorded as the patient performs the Valsalva manoeuvre. 
• The Valsalva manoeuvre consists of the patient forcing exhalation for a period of time 
on a closed airway to create an increase in pressure within the chest, which if present, 
causes blood to shunt through the PFO. A successful Valsalva will be based on the 
visualisation of atrial motion (right to left) using TTE. If the patient is unable to perform 
the Valsalva manoeuvre manually, a mouthpiece attached to a mercury manometer will 
be used to encourage patients to exhale to their best ability.  
• A PFO would be positively identified with one of the following by TTE: 1 to 9 
bubbles (grade I), 10 to 20 bubbles (grade II), and 20 bubbles (grade III) appearing in 
the left atrium. 
• The TOE is performed if clinically requested. While the results of the TTE and TCD 
are likely to be known to the performing clinician, we will subsequently anonymise 
the images are blinded adjudication.     
 
Echocardiographic Variables to be measured (in addition to assessment of septum) 
M-mode and 2D dimensions Right ventricular end-diastolic dimension 
Left ventricle (LV): end-diastolic dimension, LV end-systolic 
dimension, interventricular septal thickness, LV posterior wall 
thickness, fractional shortening 
Aortic root, Left atrial diameter 
2D area Left atrial (Apical 4 chamber view) 
Right atrial (Apical 4 chamber view) 
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2D volumes Left ventricular Simpson’s biplane 
Left ventricular Simpson’s single plane 
Left atrial Simpson’s biplane 
Left atrial Simpson’s single plane 
Right ventricular volumes  
Doppler Left ventricular outflow tract peak velocity 
Mitral E:A ratio 
Mitral deceleration time 
Tissue Doppler Medial mitral annulus (e’, a’, s’) 
Lateral mitral annulus (e’, a’, s’) 
Lateral tricuspid annulus (e’, a’, s’) 
 
3D=three-dimensional, E=early filling wave of trans-mitral flow, A=late filling wave of trans-mitral flow, 
e’=tissue velocity during early filling within the mitral annulus (MA), a’=tissue velocity during late filling within 
the MA, s’=tissue velocity during ventricular systole within the MA, E/e’=ratio of E wave to e’, S=systolic, 
D=diastolic, A=atrial contraction. 
 
6.2. Transcranial Doppler Procedure 
 
• Standard 2-D, M-Mode and Doppler measurement will be conducted using the TCD 
device and will image the middle, and posterior cerebral artery (MCA & PCA) 
• The M-mode on the TCD device will be used to assess the PFO and subsequent shunt 
in patients. The TCD machine will record both visual and audio recordings following 
the saline injection, and Valsalva.  
• The TCD device will be setup and ready to use prior to the patient arriving into the 
room. After providing the patient with a lay explanation of the process, around 20ml of 
ultrasound gel will be placed onto the side of the patient’s head, where the temporal 
window is. Any air bubbles will be smoothed out.  
• The headpiece will be placed on the patients head and the top and back strap will be 
tightened to ensure the device is secure as well as the patient being comfortable.   
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• Once secure around 50ml of gel will be placed onto each of the probes, and they will 
be attached onto the headpiece and moved into place using the adjustors ready 
Figure 4: Transcranial Doppler screenshots of Spencer shunt grades 1-5. It can be seen 
that the presence of bubbles in the cerebral arteries is obvious; besides the visual output 
on the screen, a loud signal is heard from the audio output with each bubble crossing 
the patent foramen ovale. Grade 0, no microemboli detected; grade 1, 1-10 
microemboli; grade 2, 11-30 microemboli; grade 3, 31-100 microemboli; grade 4, 101-
300 microemboli; grade 5, >300 microemboli. (Source: Cardioembolic Stroke: 




Although all of the patients in this study will have previously had a stroke or systemic 
embolism, this particular investigation involves minimal risk. Depending on how the stroke or 
systemic embolism has affected the patient (i.e. impaired right side partial paralysis) actions 
such as getting on an off the bed may cause some discomfort or risk, in this case, measures 
must be taken to ensure patient safety, such as making sure the bed is low, and secure (brake 
is on). There is a slight risk of irritation with the venous cannula, but this will be inserted by 
the clinical team as part of their usual care. Similarly, there are very minimal risks associated 
with agitated saline injection but this is also part of the patient’s clinical care. Any accidental 
injuries may be covered by ACC in New Zealand. In the very unlikely event that any 
participants requires acute care, staff will follow emergency procedures for their location. In 
the hospital, this is likely to be emergency department care, or calling a resuscitation team by 
calling 777.  
In the event of an unanticipated event of significance, such as an injury during 
examination, study personnel are required to report the event as per their individual location 






There will be three phases of patient evaluation; 
 
I. Initial TTE to diagnose or exclude any structural deficits. 
II. This will in general be followed up in the same appointment by a TTE with agitated 
saline to investigate the presence or absence of a PFO 
III. A TCD bubble study will be performed as a study procedure to investigate the presence 
or absence of a PFO, including views of the aortic arch during the agitated saline 
injection. 
IV. As part of routine clinical care, a TOE is likely to be performed in those who; 
a. are positive for a PFO with either or both TTE and TCD, or  
b. are negative for PFO on both TTE or TCD but the cardiologist or treating 
clinician has high clinical suspicion for presence of a PFO suspects  
AND are potential candidates for PFO closure. 
 
There will also be seven phases of analysis; 
 
I. Echo staff will observe the TTE for structural deficits (clinical procedure) 
II. Echo staff will observe the TTE bubble study for the presence of a PFO in the form of 
a right-to-left shunt (clinical procedure - investigators will be blinded to these findings 
up until after assessment of the TCD findings).  
III. Investigators will perform and observe the TCD recordings for both visual, and audible 
signs of a PFO (study procedure).  
IV. Results of TTE and TCD with agitated saline will be directly compared. 
V. Alternative images from the TTE (i.e. aortic arch views) will be analysed 
VI. The results from the TTE and TCD comparison, will be compared to the gold standard 




The sensitivity and specificity of TTE and TCD to detect a PFO. The gold standard 
definition of a PFO will be a PFO seen on TTE or TOE or TCD. A PFO will be deemed absent 
if both the TTE and TCD are negative and there is no further suspicion that a PFO is present, 
and/or the TOE is negative. 
 
Secondary endpoints:  
 
The sensitivity and specificity of TTE aortic view compared to normal TTE (without 
aortic view) to detect PFO. The gold standard definition of a PFO will be a PFO seen on TTE 
or TOE or TCD, a PFO will be deemed absent if both the TTE and TCD are negative, and/or 
the TOE is negative. 
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8. DATA RETENTION AND STATISTICS 
 
8.1. Sample size 
 
Recruitment into the study will be dependent on the number of cryptogenic stroke 
patients referred on for a TTE for PFO evaluation. The accrual rate is expected to be 1-3 
participants per week, based on previous records, so the final sample size will be 40-60. If 
patients are referred on for a TOE, patient participation, and therefore the “follow-up” rate is 
expected to be high due to the patients prioritising their health.  
 
8.2. Records of Data 
 
Each participant will be provided with a unique study number this number will be used 
to identify them in the database. The research team will keep records of screening, consent 
forms, medical history. All de-identified records will be kept in locked areas in the University 




The specificity and sensitivity of the TTE and TCD will be compared.  
 
Test under investigation* Gold standard of PFO (Either TTE or TCD, and/or TOE)** 
 PFO present PFO negative 
PFO present A B 
PFO negative C D 
* This is either TCD, TTE, TTE with aortic views, or TTE using different venous access 
** This is a pragmatic gold standard definition based on usual clinical practice. Ideally all 















9.1. Informed Consent 
 
Informed consent will be obtained prior to any data being collected. All participants 
will be provided with a participant information sheet that outlines the study rationale and 
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expectations of them as participants. After having read this, and having an opportunity to have 
any questions answered, and the potential participants are free to decide if they wish to proceed 
with the study. If they wish to participate in the study they are required to sign a consent form 
and can proceed to participation.  
Participant information sheets and consent forms will be HDEC-approved, and the 
participant will be required to read and review the document or have the document read to him 
or her.  One of the investigators will explain the research study to the participant and answer 
any questions that may arise.  The participant will sign the informed consent document prior 
to any study-related assessments or procedures.  Participants will be given the opportunity to 
discuss the study with anyone they choose or think about it prior to agreeing to participate.  
They may withdraw consent at any time throughout the course of the study.  A copy of the 
signed informed consent document will be given to participants for their records.  The rights 
and welfare of the participants will be protected by emphasizing to them that the quality of 
their clinical care will not be adversely affected if they decline to participate in this study. 
The consent process will be documented, and the original consent form will be filed in 
research record.   
Additionally, as the head is regarded as Tapu i.e. sacred, in certain cultures, consent 
will be granted by the participant following the complete understanding and agreement of the 




All study records and data collected during and after the study will be stored in a secure 
area at the study institution. Data will be held in a single database centrally. Each participant 
will be given a unique study identification and all information will be in an electronic database 
linked to this number and there will be no way for you to be identified from this database. 
There is a chance that we will use this database for international comparisons, which will 
include sharing of databases. All analyses will be undertaken using the unique participant 
identifier, not name.  
No information about participants will be released without their express permission. 
And the only reason for doing so will be the participant’s request or as a requirement for clinical 
follow-up. The latter will only occur with the participant’s permission. When data is released 




Scientific publication of results will be organized and determined by the study 
investigators. It is likely that primary study outcomes will be initially sent to a general 
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